

Wednesday, May 29, 2019



Volume 50 No. 5

NOTICE – Items in this issue will be listed online weekly and printed monthly.

1347 PROPERTY INSURANCE HOLDINGS INC

Earnings, 3 mos. to Mar 31(Consol. – \$000):

	2019	2018
Total Revenues	17,394	13,540
Cost & expenses	12,980	7,925
Operating income	145	2,320
Net before taxes	145	2,320
Income taxes	47	369
Net income	98	1,951
Balance for common	(252)	1,951
Earnings common share		
Primary	\$(0.04)	\$0.33
Fully Diluted	\$(0.04)	\$0.32
Common Shares:		
Full Diluted	6,013	6,093
Year-end	6,013	5,985

Consolidated Balance Sheet Items, as of (\$000):

	2019
Assets:	
Cash & equivalents	26,292
Current assets	56,353
Net property & equip.	286
Total assets	156,256
Liabilities:	
Current liabilities	14,913
Stockholders' equity	63,468
Net current assets	41,440

2U INC

Merger Completed On May 22, 2019, Co.'s wholly-owned subsidiary, Skywalker Sub, Inc. ("Merger Sub"), merged with and into Trilogy Education Services, Inc. ("Trilogy"), a workforce accelerator that prepares adult learners for high-growth careers in the digital economy, with Trilogy continuing as the surviving corporation and became a wholly-owned subsidiary of Co. (the "First Merger"), immediately following the First Merger, Trilogy merged with and into Co.'s wholly-owned subsidiary, Skywalker Purchaser, LLC ("Purchaser"), with Purchaser continuing as the surviving corporation. As a result of the First Merger, former holders of capital stock of Trilogy and options to purchase capital stock of Trilogy received their applicable portion of (a) approximately \$415,500,000 in cash and (b) approximately 4,608,100 shares of common stock of Co.

ABIOMED, INC.

Annual Report

Consolidated Income Statement, Years Ended Mar. 31 (\$):

	2019	2018	2017
Revenue	769,432,000	593,749,000	445,304,000
Cost of revenue	129,567,000	98,581,000	70,627,000
Research & development	93,503,000	75,297,000	66,386,000
Selling, general & administrative	321,550,000	262,734,000	218,153,000
Total costs & expenses	544,620,000	436,612,000	355,166,000
Income (loss) from operations	224,812,000	157,137,000	90,138,000
Investment income (expense), net	8,166,000	3,688,000	1,554,000
Other income (expense), net	30,382,000	(388,000)	(349,000)
Total other income (expense)	38,548,000	3,300,000	1,205,000
Income (loss) before provision for income taxes - United States	223,340,000	134,006,000	78,172,000

for income taxes - foreign	40,020,000	26,431,000	13,170,000
Income (loss) before income taxes	263,360,000	160,437,000	91,343,000
Current provision (benefit) for income taxes - federal	...	752,000	7,313,000
Current provision (benefit) for income taxes - state	564,000	1,491,000	5,045,000
Current provision (benefit) for income taxes - foreign	11,525,000	3,400,000	1,066,000
Total current provision (benefit) for income taxes	12,089,000	5,643,000	13,424,000
Deferred provision (benefit) for income taxes - federal	(7,153,000)	38,848,000	23,008,000
Deferred provision (benefit) for income taxes - state	(1,503,000)	(1,014,000)	(349,000)
Deferred provision (benefit) for income taxes - foreign	911,000	4,790,000	3,144,000
Total deferred provision for income taxes	(7,745,000)	42,624,000	25,803,000
Income tax provision	4,344,000	48,267,000	39,227,000
Net income (loss)	259,016,000	112,170,000	52,116,000
Weighted average shares outstanding - basic	44,911,000	44,153,000	43,238,000
Weighted average shares outstanding - diluted	46,151,000	45,849,000	44,658,000
Year end shares outstanding	45,122,985	44,375,337	43,673,286
Net income (loss) per share - basic	\$5.77	\$2.54	\$1.21
Net income (loss) per share - diluted	\$5.61	\$2.45	\$1.17
Number of full time employees	1,371	1,143	908
Number of common stockholders	422	471	517
Number of beneficiary stockholders	...	74,029	27,110

Reclassified to conform with 2018 presentation; Approximately: As of May 10, 2019; As of May 8, 2018; Approximately: As of May 12, 2017

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2019	2018
Cash & cash equivalents	121,021,000	42,975,000
Short-term marketable securities	370,677,000	319,274,000
Trade receivables	91,849,000	70,330,000
Less: allowance for		

doubtful accounts	1,040,000	320,000
Accounts receivable, net	90,809,000	70,010,000
Raw materials & supplies	24,468,000	16,481,000
Work-in-progress	35,195,000	23,179,000
Finished goods	21,279,000	10,544,000
Inventories	80,942,000	50,204,000
Prepaid expenses & other current assets	13,748,000	11,808,000
Total current assets	677,197,000	494,271,000
Long-term marketable securities	21,718,000	37,502,000
Land	7,262,000	7,680,000
Building & building improvements	86,705,000	63,700,000
Leasehold improvements	2,190,000	2,905,000
Machinery & equipment	59,146,000	42,787,000
Furniture & fixtures	11,456,000	8,104,000
Construction in progress	17,946,000	19,850,000
Property & equipment, total cost	184,705,000	145,026,000
Less: accumulated depreciation	39,700,000	27,859,000
Property & equipment, net	145,005,000	117,167,000
Goodwill	32,601,000	35,808,000
In-process research & development	15,208,000	16,705,000
Long-term deferred tax assets, net	77,502,000	70,746,000
Other assets	85,115,000	14,176,000
Total assets	1,054,346,000	786,375,000
Accounts payable	32,185,000	23,565,000
Accrued employee compensation	32,926,000	30,330,000
Accrued sales & income taxes	12,262,000	4,562,000
Accrued research & development	3,309,000	3,162,000
Accrued marketing	1,707,000	2,305,000
Accrued professional, legal & accounting fees	2,757,000	1,870,000
Accrued warranty	1,272,000	1,081,000
Other accrued expenses	3,187,000	2,837,000
Accrued expenses & other liabilities	57,420,000	46,147,000
Deferred revenue	16,393,000	14,970,000
Total current liabilities	105,998,000	84,682,000
Other long-term liabilities	1,061,000	776,000
Contingent consideration	9,575,000	10,490,000
Long-term deferred tax liabilities	822,000	903,000
Total liabilities	117,456,000	96,851,000
Common stock	451,000	444,000
Additional paid in capital	690,507,000	619,905,000
Retained earnings (accumulated deficit)	399,473,000	140,457,000
Treasury stock at cost	138,852,000	67,078,000
Accumulated other comprehensive income (loss)	(14,689,000)	(4,204,000)
Total stockholders' equity (deficit)	936,890,000	689,524,000

Recent Dividends:

1. ABIOMED, Inc. common.

No dividends paid.

Annual Dividends:

1. ABIOMED, Inc. common.

No dividends paid.

ADVANTAGE TECHNOLOGIES GROUP, INC.**Earnings, 6 mos. to Mar 31**(Consol. - \$):

	2019	2018
Total Revenues	28,545,389	23,934,293
Cost & expenses	30,704,336	24,284,178
Operating income	(2,158,947)	(349,885)
Interest expense	44,638	142,016
Other income (expense), net	11,741	(258,558)
Net before taxes	(2,191,844)	(750,459)
Income taxes	63,000	216,000
Net income	(2,254,844)	(966,459)
Earnings common share		
Primary	\$(0.22)	\$(0.09)
Fully Diluted	\$(0.22)	\$(0.09)
Common Shares:		
Full Diluted	10,361,292	10,239,353
Year-end	10,361,292	10,306,145

AKCEA THERAPEUTICS INC**Earnings, 3 mos. to Mar 31**(Consol. - \$000):

	2019	2018
Total Revenues	163,816	17,108
Cost & expenses	137,609	47,435
Operating income	26,207	(30,327)
Other income (expense), net	(112)	(168)
Gains or losses	1,224	868
Net before taxes	27,319	
Income taxes	132	
Net income	27,187	(29,627)
Earnings common share		
Primary	\$0.35	\$(0.44)
Fully Diluted	\$0.34	\$(0.44)
Common Shares:		
Full Diluted	68,582	45,448
Year-end	92,635	66,804

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2019	2018
	201,027	17,108
Current assets	350,885	47,435
Net property & equip.	5,336	(30,327)
Total assets	458,717	(112)
Liabilities:		
Current liabilities	53,110	868
Stockholders' equity	388,864	27,319
Net current assets	297,775	132

ALECTOR INC**Earnings, 3 mos. to Mar 31**(Consol. - \$000):

	2019	2018
Total Revenues	5,605	4,920
Cost & expenses	26,366	14,145
Operating income	(20,761)	(9,225)
Other income (expense), net	2,201	788
Net income	(18,560)	(8,437)
Earnings common share		
Primary	\$(0.42)	\$(0.78)
Fully Diluted	\$(0.42)	\$(0.78)
Common Shares:		
Full Diluted	43,828	10,858
Year-end	68,872	13,765

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2019	2018
	60,954	4,920
Current assets	442,114	14,145
Net property & equip.	21,733	(9,225)
Total assets	496,044	2,201
Liabilities:		
Current liabilities	55,834	788
Long-term debt	96	
Stockholders' equity	266,186	20,761
Net current assets	386,280	11,916

ALPHATEC HOLDINGS INC**Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2019	2018
Total Revenues	24,555,000	21,307,000
Cost & expenses	35,139,000	21,797,000
Operating income	(10,766,000)	(667,000)
Other income (expense), net	(2,119,000)	(1,645,000)
Net before taxes	(12,885,000)	(2,312,000)
Income taxes	31,000	(458,000)

Income contin. oper. (12,916,000) (1,854,000)

Net income (12,968,000) (1,916,000)

Earnings common share

Primary \$(0.29) \$(0.09)

Fully Diluted \$(0.29) \$(0.09)

Common Shares:

Full Diluted 45,020,000 21,212,000

Year-end 46,578,000 25,547,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	2019	2018
	16,419,000	17,108
Inventories	31,166,000	47,435
Current assets	63,749,000	47,435
Net property & equip.	12,821,000	(30,327)
Total assets	119,417,000	(112)
Liabilities:		
Current liabilities	27,627,000	868
Long-term debt	42,559,000	27,319
Stockholders' equity	9,250,000	20,761
Net current assets	36,122,000	13,765

ALPINE IMMUNE SCIENCES INC**Earnings, 3 mos. to Mar 31**(Consol. - \$000):

	2019	2018
Total Revenues	315	315
Cost & expenses	12,695	5,900
Operating income	(12,695)	(5,585)
Interest expense	70	78
Net before taxes	(5,358)	(5,358)
Income taxes	(52)	(52)
Net income	(12,381)	(5,306)
Earnings common share		
Primary	\$(0.70)	\$(0.38)
Fully Diluted	\$(0.70)	\$(0.38)
Common Shares:		
Full Diluted	17,672	13,845
Year-end	18,561	13,846

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2019	2018
	41,437	315
Current assets	64,895	5,900
Net property & equip.	1,221	(5,585)
Total assets	67,105	(112)
Liabilities:		
Current liabilities	8,848	78
Long-term debt	1,674	
Stockholders' equity	56,583	27,319
Net current assets	56,047	13,765

ALTAIR ENGINEERING INC**Earnings, 3 mos. to Mar 31**(Consol. - \$000):

	2019	2018
Total Revenues	91,731	76,882
Net Sales	77,616	63,068
Cost & expenses	85,521	77,929
Operating income	4,270	(1,990)
Interest expense	16	611
Other income (expense), net	103	85
Foreign currency	797	(444)
Net before taxes	5,154	(2,960)
Income taxes	1,234	(772)
Net income	3,920	(2,188)
Earnings common share		
Primary	\$0.06	\$(0.04)
Fully Diluted	\$0.05	\$(0.04)
Common Shares:		
Full Diluted	72,390	50,132
Year-end	63,865	50,132

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2018	2018
	63,196	76,882
Inventories	1,051	63,068
Current assets	167,643	77,929
Net property & equip.	30,501	(1,990)
Total assets	310,822	76,882
Liabilities:		
Current liabilities	218,679	611
Long-term debt	526	85
Stockholders' equity	65,125	72,912
Net current assets	(51,036)	70,912

ALTIGEN COMMUNICATIONS INC**Earnings, 6 mos. to Mar 31**(Consol. - \$):

	2019	2018
Total Revenues	5,319,000	4,774,000
Cost & expenses	4,297,000	4,052,000
Operating income	1,022,000	722,000
Net before taxes	1,031,000	723,000
Income taxes	16,000	2,000
Net income	1,015,000	721,000
Earnings common share		
Primary	\$0.04	\$0.03
Fully Diluted	\$0.04	\$0.03
Common Shares:		
Full Diluted	25,364,000	24,537,000
Year-end	22,887,246	22,817,246

ALTIMMUNE INC**Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2019	2018
Total Revenues	2,955,592	2,690,980
Cost & expenses	5,284,153	8,685,541
Operating income	(2,328,561)	(5,994,561)
Interest income	185,246	31,590
Interest expense	740	870
Other income (expense), net	46,749	1,798,665
Net before taxes	(4,165,176)	(4,165,176)
Income taxes		(991,638)
Net income	(2,097,306)	(3,173,538)
Balance for common	(2,550,231)	(5,064,859)
Earnings common share		
Primary	\$(0.27)	\$(7.49)
Fully Diluted	\$(0.27)	\$(7.49)
Common Shares:		
Full Diluted	9,489,765	676,552
Year-end	13,450,680	741,678

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	2019	2018
	44,300,170	2,690,980
Current assets	49,414,052	8,685,541
Net property & equip.	1,282,752	(5,994,561)
Total assets	65,373,830	(112)
Liabilities:		
Current liabilities	3,676,389	870
Long-term debt	334,460	
Stockholders' equity	59,322,110	27,319
Net current assets	45,737,663	13,765

ANALOG DEVICES INC**Earnings, 6 mos. to (Consol. - \$000):**

	05/04/19	05/05/18
Total Revenues	3,067,703	3,130,372
Cost & expenses	1,927,597	1,971,829
Operating income	925,521	944,395
Interest income	5,616	4,004
Interest expense	118,429	132,822
Other income (expense), net	(4,365)	(105)
Net before taxes	808,343	815,472
Income taxes	85,400	121,904
Net income	722,943	693,568
Balance for common	721,011	690,741
Earnings common share		
Primary	\$1.95	\$1.87
Fully Diluted	\$1.93	\$1.84
Common Shares:		
Full Diluted	372,912	374,430
Year-end	369,761	370,897

ANGI HOMESERVICES INC**Earnings, 3 mos. to Mar 31**(Consol. - \$000):

	2019	2018
Total Revenues	303,443	255,311
Cost & expenses	285,546	243,577
Operating income	(3,641)	(10,756)
Other income (expense), net	2,287	356
Net before taxes	(4,364)	(13,099)
Income taxes	(14,215)	(3,985)
Net income	9,851	(9,114)
Earnings common share		
Primary	\$0.02	\$(0.02)
Fully Diluted	\$0.02	\$(0.02)
Common Shares:		
Full Diluted	523,125	478,309
Year-end	506,170	479,238

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	345,351
Current assets	479,554
Net property & equip.	79,618
Total assets	1,920,202
Liabilities:	
Current liabilities	218,960
Long-term debt	241,664
Stockholders' equity	1,322,858
Net current assets	260,594

APPLIED MATERIALS, INC.**Earnings, 6 mos. to (Consol. - \$000):**

	04/28/19	04/29/18
Net Sales	7,292,000	8,784,000
Cost & expenses	5,608,000	6,277,000
Operating income	1,684,000	2,507,000
Net before taxes	1,647,000	2,444,000
Income taxes	210,000	1,179,000
Net income	1,437,000	1,265,000
Earnings common share		
Primary	\$1.51	\$1.21
Fully Diluted	\$1.50	\$1.20
Common Shares:		
Full Diluted	957,000	1,056,000
Year-end	936,000	

APTEVO THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	18,462	17,572
Operating income	(11,440)	(13,501)
Other income (expense), net	(578)	(353)
Net income	(12,018)	(13,854)
Earnings common share		
Primary	\$(0.44)	\$(0.63)
Fully Diluted	\$(0.44)	\$(0.63)
Common Shares:		
Full Diluted	27,568	22,025
Year-end	45,090	22,442

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	37,011
Inventories	4,346
Current assets	57,642
Net property & equip.	4,978
Total assets	80,841
Liabilities:	
Current liabilities	18,290
Long-term debt	19,415
Stockholders' equity	39,130
Net current assets	39,352

APTINX INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	890	2,464
Cost & expenses	18,215	14,273
Operating income	(17,325)	(11,809)
Other income (expense), net	614	137
Net income	(16,711)	(11,672)
Earnings common share		
Primary	\$(0.50)	\$(2.17)
Fully Diluted	\$(0.50)	\$(2.17)
Common Shares:		
Full Diluted	33,390	5,378
Year-end	33,437	5,415

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	136,580
Current assets	138,765
Net property & equip.	1,555
Total assets	140,993
Liabilities:	
Current liabilities	5,923
Stockholders' equity	134,686
Net current assets	132,842

ARCH THERAPEUTICS INC**Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2019	2018
Cost & expenses	3,275,190	3,596,218
Operating income	(3,275,190)	(3,596,218)
Other income (expense), net	844,915	2,430,033

Net income	(2,430,275)	(1,166,185)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	162,159,275	150,222,429
Year-end	164,961,849	154,052,013

ARK RESTAURANTS CORP

Acquisition Completed On May 15, 2019, Co., through a newly formed wholly-owned subsidiary, acquired the assets of a restaurant and bar named JB's on the Beach located in Deerfield Beach, FL, from Boyle Beach House LLC, for \$7,000,000 plus inventory.

ARK RESTAURANTS CORP**Earnings, 6 mos. to (Consol. - \$000):**

	03/30/19	03/31/18
Total Revenues	75,859	74,628
Cost & expenses	73,082	71,726
Operating income	384	320
Interest income	29	28
Interest expense	658	520
Net before taxes	(245)	(172)
Income taxes	446	(1,223)
Net income	(691)	1,051
Earnings common share		
Primary	\$(0.21)	\$0.29
Fully Diluted	\$(0.21)	\$0.28
Common Shares:		
Full Diluted	3,475	3,552
Year-end	3,477	3,437

AROTECH CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	20,778,639	27,248,509
Cost & expenses	21,356,123	25,677,790
Operating income	(947,687)	1,055,808
Other income (expense), net	(298,445)	(213,105)
Net before taxes	(1,246,132)	842,703
Income taxes	160,881	247,114
Net income	(1,407,013)	595,589
Earnings common share		
Primary	\$(0.05)	\$0.02
Fully Diluted	\$(0.05)	\$0.02
Common Shares:		
Full Diluted	26,387,285	26,447,090
Year-end	26,617,460	26,452,462

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	4,523,949
Inventories	9,452,464
Current assets	54,875,606
Net property & equip.	8,931,136
Total assets	125,000,319
Liabilities:	
Current liabilities	30,361,983
Long-term debt	6,006,573
Stockholders' equity	75,434,644
Net current assets	24,513,623

AVEDRO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	8,773	5,154
Cost & expenses	16,790	10,860
Operating income	(8,017)	(5,706)
Interest income	195	6
Interest expense	700	627
Other income (expense), net	169	(307)
Net income	(8,353)	(6,634)
Earnings common share		
Primary	\$(1.00)	\$(4.85)
Fully Diluted	\$(1.00)	\$(4.85)
Common Shares:		
Full Diluted	8,369	1,368
Year-end	17,067	1,403

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	64,809
Inventories	4,473
Current assets	83,371
Net property & equip.	1,447
Total assets	85,749

Liabilities:	
Current liabilities	8,684
Long-term debt	20,128
Stockholders' equity	56,272
Net current assets	74,687

AVROBIO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	17,700	7,788
Operating income	(17,700)	(7,788)
Interest income	657	158
Other income (expense), net	(60)	(612)
Net income	(17,103)	(8,242)
Balance for common	(17,103)	(10,485)
Earnings common share		
Primary	\$(0.72)	\$(4.51)
Fully Diluted	\$(0.72)	\$(4.51)
Common Shares:		
Full Diluted	23,894	2,325
Year-end	23,954	2,336

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	108,476
Current assets	113,679
Net property & equip.	2,864
Total assets	117,368
Liabilities:	
Current liabilities	9,935
Stockholders' equity	106,788
Net current assets	103,744

BERRY PETROLEUM CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	76,539	97,284
Cost & expenses	90,268	72,692
Operating income	(47,196)	7,349
Interest expense	8,805	7,796
Other income (expense), net	(231)	8,955
Net before taxes	(47,196)	7,349
Income taxes	(13,098)	939
Net income	(34,098)	6,410
Balance for common	(34,098)	760
Earnings common share		
Primary	\$(0.42)	\$0.02
Fully Diluted	\$(0.42)	\$0.02
Common Shares:		
Full Diluted	81,765	38,827
Year-end	81,879	32,955

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	1,662
Current assets	97,802
Net property & equip.	1,469,127
Total assets	1,583,203
Liabilities:	
Current liabilities	114,631
Long-term debt	391,947
Stockholders' equity	939,129
Net current assets	(16,829)

BIOSPECIFICS TECHNOLOGIES CORP.

Co. Repurchasing Certain Securities On May 23, 2019, Co. announced that the Executive Committee of its Board of Directors has authorized a stock repurchase program under which Co. was authorized to repurchase up to \$4,000,000 of its outstanding common stock.

BLINK CHARGING CO**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	577,390	595,920
Cost & expenses	2,892,878	4,397,859
Operating income	(2,315,488)	(3,801,939)
Other income (expense), net	95,789	7,425,139
Gains or losses	310,000	
Net income	(1,893,627)	2,204,088
Balance for common	(1,893,627)	(21,862,643)
Earnings common share		
Primary	\$(0.07)	\$(2.58)
Fully Diluted	\$(0.07)	\$(2.58)
Common Shares:		
Full Diluted	26,171,070	8,472,092
Year-end	26,223,809	22,181,901

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	12,599,600
Inventories	1,872,667
Current assets	18,499,957
Net property & equip.	415,196
Total assets	19,388,142
Liabilities:	
Current liabilities	4,504,286
Stockholders' equity	14,619,912
Net current assets	13,995,671

BLUEKNIGHT ENERGY PARTNERS LP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	93,732	44,660
Cost & expenses	85,692	38,845
Operating income	8,040	5,815
Interest expense	4,271	3,569
Gains or losses	2,225	
Net before taxes	3,769	4,471
Income taxes	12	29
Net income	3,757	4,442
Earnings common share		
Primary	\$(0.06)	\$(0.05)
Fully Diluted	\$(0.06)	\$(0.05)
Common Shares:		
Full Diluted	40,678	40,289
Year-end	41,940	40,321

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	1,209
Current assets	37,833
Net property & equip.	243,063
Total assets	319,656
Liabilities:	
Current liabilities	54,671
Long-term debt	252,592
Net current assets	(16,838)

BSQUARE CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	15,096	20,678
Cost & expenses	17,975	23,156
Operating income	(2,879)	(2,478)
Other income (expense), net	33	44
Net income	(2,846)	(2,434)
Earnings common share		
Primary	\$(0.22)	\$(0.19)
Fully Diluted	\$(0.22)	\$(0.19)
Common Shares:		
Full Diluted	12,795	12,673
Year-end	12,823	12,689

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	7,489
Current assets	26,428
Net property & equip.	989
Total assets	29,673
Liabilities:	
Current liabilities	12,464
Stockholders' equity	15,673
Net current assets	13,964

CALUMET SPECIALTY PRODUCT PARTNERS LP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Net Sales	851,300	750,500
Cost & expenses	817,500	709,200
Operating income	33,800	41,300
Interest expense	32,300	45,200
Other income (expense), net	5,700	900
Gains or losses	9,100	(100)
Net before taxes	16,300	(3,100)
Income taxes	(100)	(200)
Income contin. oper.	(2,900)	(2,900)
Net income	16,400	(4,800)
Earnings common share		
Primary	\$0.20	\$(0.06)
Fully Diluted	\$0.20	\$(0.06)
Common Shares:		
Full Diluted	78,175	78,045
Year-end	77,470	78,475

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	152,900
Inventories	291,100
Current assets	755,700
Net property & equip.	1,069,000
Total assets	2,270,400
Liabilities:	
Current liabilities	566,200
Long-term debt	1,541,200
Net current assets	189,500

CANCER GENETICS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	6,839,000	7,667,000
Cost & expenses	9,757,000	12,614,000
Operating income	(2,918,000)	(4,947,000)
Interest income	2,000	21,000
Interest expense	1,725,000	239,000
Other income (expense), net	24,000	709,000
Net income	(4,617,000)	(4,456,000)
Earnings common share		
Primary	\$(0.09)	\$(0.16)
Fully Diluted	\$(0.09)	\$(0.16)
Common Shares:		
Full Diluted	48,933,000	27,049,000
Year-end	56,276,000	27,730,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	697,000
Current assets	10,333,000
Net property & equip.	3,821,000
Total assets	38,492,000
Liabilities:	
Current liabilities	28,319,000
Long-term debt	294,000
Stockholders' equity	7,679,000
Net current assets	(17,986,000)

CANTERBURY PARK HOLDING CORP (NEW)**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Cost & expenses	10,988,039	10,228,048
Operating income	(22,761)	1,356,753
Interest income	63,240	12,407
Net before taxes	40,479	1,369,160
Income taxes	(16,093)	379,470
Net income	56,572	989,690
Earnings common share		
Primary	\$0.01	\$0.22
Fully Diluted	\$0.01	\$0.22
Common Shares:		
Full Diluted	4,613,245	4,490,863
Year-end	4,574,658	4,449,987

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	370,592
Inventories	315,783
Current assets	8,986,161
Net property & equip.	40,720,542
Total assets	61,910,475
Liabilities:	
Current liabilities	10,976,145
Long-term debt	92,244
Stockholders' equity	46,771,947
Net current assets	(1,989,984)

CARDAX INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	164,972	313,310
Cost & expenses	1,267,973	1,352,363
Deprec., depl. & amort.	11,262	9,605
Operating income	(1,114,263)	(1,048,658)
Other income (expense), net		556
Net income	(1,135,420)	(1,047,864)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	133,947,091	122,674,516
Year-end	134,686,596	122,859,700

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	73,355
Inventories	1,423,002
Current assets	1,823,887
Total assets	2,289,072
Liabilities:	
Current liabilities	5,630,439
Long-term debt	1,000,000
Stockholders' equity	(4,445,436)
Net current assets	(3,806,552)

CARDLYTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	35,988	32,713
Cost & expenses	41,528	41,620
Operating income	(6,501)	(9,817)
Interest income	185	
Interest expense	489	
Other income (expense), net		(9,172)
Foreign currency	491	683
Net income	(6,314)	(20,055)
Balance for common	(6,314)	(20,212)
Earnings common share		
Primary	\$(0.28)	\$(1.54)
Fully Diluted	\$(0.28)	\$(1.54)
Common Shares:		
Full Diluted	22,503	13,093
Year-end	22,570	20,226

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	36,428
Current assets	117,298
Net property & equip.	11,351
Total assets	146,467
Liabilities:	
Current liabilities	49,555
Long-term debt	46,691
Stockholders' equity	47,177
Net current assets	67,743

CARGURUS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	135,270	98,575
Cost & expenses	126,768	91,383
Operating income	7,435	6,459
Other income (expense), net	902	(9)
Net before taxes	9,081	6,741
Income taxes	(3,503)	1,246
Net income	12,584	5,495
Earnings common share		
Primary	\$0.11	\$0.05
Fully Diluted	\$0.11	\$0.05
Common Shares:		
Full Diluted	113,406	113,341
Year-end	111,073	106,128

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	29,939
Current assets	179,406
Net property & equip.	26,550
Total assets	331,927
Liabilities:	
Current liabilities	65,474
Stockholders' equity	211,009
Net current assets	113,932

CATABASIS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	6,334	7,639
Operating income	(6,334)	(7,639)
Interest income	226	32
Interest expense		57
Other income (expense), net	70	12
Net income	(6,038)	(7,652)
Earnings common share		
Primary	\$(0.62)	\$(2.88)
Fully Diluted	\$(0.62)	\$(2.88)
Common Shares:		
Full Diluted	9,686	2,656
Year-end	11,496	2,904

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	11,652	
Current assets	52,649	
Net property & equip.	48	
Total assets	54,497	
Liabilities:		
Current liabilities	4,298	
Stockholders' equity	49,869	
Net current assets	48,351	

CBA FLORIDA INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Cost & expenses	103,431	428,923
Operating income	(103,431)	(428,923)
Other income (expense), net	48,092	6,823
Net before taxes	(55,339)	
Income taxes	(12,888)	
Income discount. oper.	458,749	
Net income	(42,451)	36,649
Earnings common share		
Common Shares:		
Full Diluted	1,272,066,146	272,066,146
Year-end	1,272,066,146	272,066,146

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	11,893,145	
Current assets	12,009,600	
Total assets	15,043,972	
Liabilities:		
Current liabilities	928,897	
Stockholders' equity	14,115,075	
Net current assets	11,080,703	

CBAK ENERGY TECHNOLOGY INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	5,171,675	3,312,797
Cost & expenses	7,710,070	5,726,260
Operating income	(2,538,395)	(2,413,463)
Other income (expense), net	(268,938)	(154,370)
Net income	(2,807,333)	(2,567,833)
Earnings common share		
Primary	\$(0.10)	\$(0.10)
Fully Diluted	\$(0.10)	\$(0.10)
Common Shares:		
Full Diluted	28,610,072	26,502,086
Year-end	31,745,518	26,231,817

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	245,688	
Inventories	9,215,623	
Current assets	50,367,966	
Net property & equip.	44,464,272	
Total assets	123,246,090	
Liabilities:		
Current liabilities	85,136,236	
Long-term debt	21,127,024	
Stockholders' equity	2,909,836	
Net current assets	(34,768,270)	

CHIASHA INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Cost & expenses	8,921,000	7,297,000
Operating income	(8,921,000)	(7,297,000)
Other income (expense), net	184,000	230,000
Net before taxes	(8,737,000)	(7,067,000)
Income taxes	13,000	(24,000)
Net income	(8,750,000)	(7,043,000)
Earnings common share		
Primary	\$(0.36)	\$(0.29)
Fully Diluted	\$(0.36)	\$(0.29)
Common Shares:		
Full Diluted	24,466,617	24,381,924
Year-end	24,489,959	24,383,994

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	10,074,000	
Current assets	53,509,000	
Net property & equip.	102,000	
Total assets	54,873,000	

Liabilities:

Current liabilities	28,190,000
Stockholders' equity	26,033,000
Net current assets	25,319,000

CHINA XD PLASTICS CO., LTD**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	301,466,007	310,453,033
Cost & expenses	270,251,730	271,561,493
Operating income	31,214,277	38,891,540
Interest income	435,779	2,312,623
Interest expense	17,500,277	12,894,205
Other income (expense), net	2,094,937	1,477,559
Gains or losses	518,491	(520,981)
Net before taxes	14,622,342	25,310,728
Income taxes	3,641,627	6,210,827
Net income	10,980,715	19,099,901
Balance for common	8,356,451	14,415,107
Earnings common share		
Primary	\$0.16	\$0.29
Fully Diluted	\$0.16	\$0.29
Common Shares:		
Full Diluted	50,948,841	49,727,731
Year-end	50,948,841	49,727,731

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	78,891,580	
Inventories	793,243,874	
Current assets	1,549,778,382	
Net property & equip.	770,413,511	
Total assets	2,893,793,916	
Liabilities:		
Current liabilities	1,614,548,420	
Long-term debt	188,183,909	
Stockholders' equity	774,568,944	
Net current assets	(64,770,038)	

CISCO SYSTEMS INC**Earnings, 9 mos. to (Consol. - \$000):**

	04/27/19	04/28/18
Net Sales	38,476,000	36,486,000
Cost & expenses	27,835,000	27,335,000
Operating income	10,529,000	8,963,000
Other income (expense), net	(51,000)	(86,000)
Gains or losses	41,000	134,000
Net before taxes	10,867,000	9,447,000
Income taxes	1,452,000	13,140,000
Net income	9,415,000	(3,693,000)
Earnings common share		
Primary	\$2.11	\$(0.76)
Fully Diluted	\$2.09	\$(0.76)
Common Shares:		
Full Diluted	4,509,000	4,892,000
Year-end	4,313,000	4,734,000

CISCO SYSTEMS INC

Official Changes On May 22, 2019, Co. announced the appointment of Wesley G. Bush, chairman of Northrop Grumman Corporation, to its Board of Directors, effective May 21, 2019.

CITI TRENDS INC

Dividend Announcement On May 23, 2019, Co.'s Board of Directors declared a quarterly dividend of \$0.08 per common share, payable on June 18, 2019, to shareholders of record as of the close of business on June 4, 2019.

COMMERCIAL VEHICLE GROUP INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

	2018	2017	2016
		(revised)	(revised)
Revenues	897,737	755,231	662,112
Cost of revenues	768,885	663,513	575,409
Gross profit	128,852	91,718	86,703
Selling, general & administrative expenses	60,679	59,547	60,482
Amortization expense	1,300	1,320	1,305
Operating income (loss)	66,873	30,851	24,916
Other income (expense)	1,311	1,943	1,236
Interest expense	14,676	19,149	19,318

Income (loss)

before provision (benefit) for income taxes - domestic	27,024	(2,093)	(13,928)
Income (loss) before provision (benefit) for income taxes - foreign	26,484	15,738	20,762
Income (loss) before provision (benefit) for income taxes - federal	(3,432)	2,954	(4)
Current provision (benefit) for income taxes - state & local	123	362	(27)
Current provision (benefit) for income taxes - foreign	6,365	4,042	2,605
Total current provision (benefit) for income taxes	3,056	7,358	2,574
Deferred provision (benefit) for income taxes - federal	5,243	7,716	(1,801)
Deferred provision (benefit) for income taxes - state	179	(371)	1,021
Deferred provision (benefit) for income taxes - foreign	518	647	(1,745)
Total deferred provision (benefit) for income taxes	5,940	7,992	(2,525)
Provision (benefit) for income taxes	8,996	15,350	49
Net income (loss) attributable to Commercial Vehicle Group, Inc.	44,512	(1,705)	6,785
Weighted average shares outstanding - basic	30,277	29,942	29,530
Weighted average shares outstanding - diluted	30,587	29,942	29,878
Year end shares outstanding	29,179	29,043	29,871
Net earnings (loss) per share - basic	\$1.47	\$(0.06)	\$0.23
Net earnings (loss) per share - diluted	\$1.46	\$(0.06)	\$0.23
Number of full time employees	7,000
Total number of employees	8,355	8,250	...
Number of common stockholders	169	164	168
Foreign currency translation adjustments	...	7,141	(3,234)

Reclassified to conform with 2019 presentation; Approximate; As is; As of March 11, 2019; As of March 12, 2018; As of March 9, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
		(revised)
Cash	70,913	52,244
Accounts receivable, gross	139,763	113,837
Less: allowances	5,139	5,242

Accounts receivable, net	134,624	108,595
Raw materials	66,965	73,026
Work in process	12,333	10,136
Finished goods	13,061	15,853
Inventories	92,359	99,015
Other current assets	16,828	14,792
Total current assets	314,724	274,646
Land & buildings	26,240	25,942
Machinery & equipment	175,990	183,556
Construction in progress	6,650	2,685
Less: accumulated depreciation	143,781	147,553
Property, plant & equipment, net	65,099	64,630
Goodwill	7,576	8,045
Intangible assets, gross	22,368	23,081
Less: accumulated amortization - intangible assets	9,568	8,533
Intangible assets, net	12,800	14,548
Deferred income taxes, net	15,348	20,273
Other assets	2,583	2,246
Total assets	418,130	384,388
Accounts payable	86,645	86,608
Accrued compensation & benefits	12,893	12,904
Accrued taxes payable	5,275	3,564
Accrued warranty costs	3,911	3,490
Accrued insurance	2,485	2,432
Accrued legal & professional fees	1,710	1,588
Accrued freight	1,559	1,544
Accrued services	1,106	1,207
Deferred tooling revenue	1,466	806
Other accrued & other liabilities	6,564	6,409
Current maturities of long-term debt	9,102	3,191
Total current liabilities	132,716	123,743
Term loan & security agreement	163,758	166,949
Less current portion of long-term debt	9,102	3,191
Pension & other post-retirement benefits	12,065	15,450
Other long-term liabilities	3,655	6,695
Total liabilities	303,092	309,646
Common stock	318	304
Treasury stock, at cost	10,245	9,114
Additional paid-in capital	243,007	239,870
Retained earnings (deficit)	(70,571)	(115,083)
Foreign currency items	(22,847)	(17,172)
Derivative instruments	496	...
Pension & postretirement benefit plans	(25,120)	(24,063)
Accumulated other comprehensive income (loss)	(47,471)	(41,235)
Total Commercial Vehicle Group (CVG) stockholders' equity (deficit)	115,038	74,742
Total stockholders' equity (deficit)	115,038	74,742

Recent Dividends:**1. Commercial Vehicle Group Inc common.**

No dividends paid.

Annual Dividends:**1. Commercial Vehicle Group Inc common.**

No dividends paid.

COMVAULT SYSTEMS INC

Official Changes On May 22, 2019, Co. appointed Grace Ho as its new Area Vice President for Association of Southeast Asian Nations (ASEAN) and Chief of Staff (APAC), based in Singapore.

COMSCORE INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	102,294	105,919
Cost & expenses	116,780	143,660

Operating income	(22,591)	(46,285)
Interest expense	6,759	2,905
Other income (expense), net	2,969	77
Foreign currency	38	(922)
Net before taxes	(26,343)	(50,035)
Income taxes	1,171	1,415
Net income	(27,514)	(51,450)
Earnings common share		
Primary	\$(0.46)	\$(0.93)
Fully Diluted	\$(0.46)	\$(0.93)
Common Shares:		
Full Diluted	59,958	55,227
Year-end	59,958	55,018

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	42,843	
Current assets	124,578	
Net property & equip.	28,406	
Total assets	962,570	
Liabilities:		
Current liabilities	161,467	
Long-term debt	178,913	
Stockholders' equity	533,938	
Net current assets	(36,889)	

CONRAD INDUSTRIES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	47,405	50,288
Cost & expenses	47,953	49,315
Operating income	(548)	973
Interest expense	103	116
Other income (expense), net	210	2
Net before taxes	(441)	859
Income taxes	(134)	273
Net income	(307)	586
Earnings common share		
Primary	\$(0.06)	\$0.12
Fully Diluted	\$(0.06)	\$0.12
Common Shares:		
Full Diluted	5,018	5,018
Year-end	5,018	5,018

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	41,609	
Inventories	3,851	
Current assets	100,985	
Net property & equip.	59,882	
Total assets	160,939	
Liabilities:		
Current liabilities	34,923	
Long-term debt	10,000	
Stockholders' equity	111,819	
Net current assets	66,062	

CRAY INC

Merger Development On May 16, 2019, Co., Hewlett Packard Enterprise Co. ("HPE"), and Canopy Merger Sub, Inc., a wholly-owned subsidiary of HPE ("Merger Sub"), entered into an Agreement and Plan of Merger ("Merger Agreement"). The Board of Directors of Co. (the "Board") has unanimously determined that the terms of the Merger Agreement and the transactions contemplated thereby, including the Merger (as defined below), are fair to and in the best interests of Co. and its shareholders and approved the Merger Agreement and the transactions contemplated thereby, and unanimously resolved to recommend that Co.'s shareholders vote to approve the Merger Agreement. Pursuant to the terms of the Merger Agreement, and subject to the conditions specified in the Merger Agreement, Merger Sub will merge with and into Co., and Co. will become a wholly-owned subsidiary of HPE (the "Merger"). If the Merger is completed, Cray shareholders will be entitled to receive \$35.00 in cash, in a transaction valued at approximately \$1,300,000,000, net of cash, (the "Merger Consideration") for each share of Co.'s common stock ("Co. Common Stock") owned by them as of immediately prior to the effective time of the Merger (the "Effective Time"). The transaction is expected to close by the first quarter of HPE's fiscal year 2020, subject to regulatory approvals and other customary closing conditions.

CREDITRISKMONITOR.COM, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	3,495,809	3,371,924
Cost & expenses	3,636,404	3,672,115

Deprec., depl. & amort.	50,989	47,048
Operating income	(191,584)	(347,239)
Other income (expense), net	40,890	21,042
Net before taxes	(150,694)	(326,197)
Income taxes	(14,226)	(70,761)
Net income	(136,468)	(255,436)

Earnings common share

Primary	\$(0.01)	\$(0.02)
Fully Diluted	\$(0.01)	\$(0.02)

Common Shares:

Full Diluted	10,722,401	10,722,401
Year-end	10,722,401	10,722,401

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	8,389,953	
Current assets	10,999,376	
Net property & equip.	532,624	
Total assets	16,043,457	
Liabilities:		
Current liabilities	10,320,416	
Stockholders' equity	2,835,628	
Net current assets	678,960	

CRINETICS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	367	442
Cost & expenses	10,411	5,968
Operating income	(10,044)	(5,526)
Interest income	1,010	64
Other income (expense), net	18	(2)
Net income	(9,016)	(5,464)
Earnings common share		
Primary	\$(0.37)	\$(2.92)
Fully Diluted	\$(0.37)	\$(2.92)

Common Shares:

Full Diluted	24,095	1,870
Year-end	24,115	2,191

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	62,833	
Current assets	159,115	
Net property & equip.	4,465	
Total assets	166,763	
Liabilities:		
Current liabilities	8,818	
Stockholders' equity	152,394	
Net current assets	150,297	

CUMBERLAND PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	11,902,747	8,587,605
Cost & expenses	11,057,898	10,403,692
Operating income	(176,796)	(2,452,222)
Interest income	115,861	82,494
Interest expense	60,911	18,302
Net before taxes	(121,846)	(2,388,030)
Income taxes	(81,428)	4,159
Net income	(40,418)	(2,392,189)

Earnings common share

Primary	\$(0.15)	\$(0.15)
Fully Diluted	\$(0.15)	\$(0.15)

Common Shares:

Full Diluted	15,472,952	15,689,240
Year-end	15,547,517	15,727,250

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	24,609,415	
Inventories	11,259,233	
Current assets	57,966,169	
Net property & equip.	744,085	
Total assets	114,617,629	
Liabilities:		
Current liabilities	27,998,645	
Long-term debt	20,000,000	
Stockholders' equity	55,431,533	
Net current assets	29,967,524	

CURAEGIS TECHNOLOGIES INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Cost & expenses	881,000	1,067,000
Operating income	(874,000)	(1,059,000)
Other income (expense), net		1,000
Net income	(1,148,000)	(1,295,000)
Balance for common	(1,202,000)	(1,349,000)
Earnings common share		
Primary	\$(0.02)	\$(0.03)
Fully Diluted	\$(0.02)	\$(0.03)
Common Shares:		
Full Diluted	50,401,000	49,031,000
Year-end	50,400,545	49,059,546

Consolidated Balance Sheet Items, as of (\$):

	2019	2018
Assets:		
Cash & equivalents	51,000	
Current assets	64,000	
Net property & equip.	55,000	
Total assets	355,000	
Liabilities:		
Current liabilities	2,575,000	
Long-term debt	7,155,000	
Stockholders' equity	(9,497,000)	
Net current assets	(2,511,000)	

CYCLERION THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	37,381	25,283
Operating income	(37,381)	(25,283)
Net income	(37,381)	(25,283)
Earnings common share		
Year-end	27,402	

Consolidated Balance Sheet Items, as of (\$000):

	2019	2018
Assets:		
Current assets	939	
Net property & equip.	8,815	
Total assets	9,773	
Liabilities:		
Current liabilities	17,473	
Stockholders' equity	(7,752)	
Net current assets	(16,534)	

DECIPHERA PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	49,025	21,951
Operating income	(49,025)	(21,951)
Interest expense	13	22
Other income (expense), net	1,654	543
Net income	(47,384)	(21,430)
Earnings common share		
Primary	\$(1.25)	\$(0.66)
Fully Diluted	\$(1.25)	\$(0.66)
Common Shares:		
Full Diluted	38,057	32,594
Year-end	38,189	32,594

Consolidated Balance Sheet Items, as of (\$000):

	2019	2018
Assets:		
Cash & equivalents	82,228	
Current assets	266,445	
Net property & equip.	1,504	
Total assets	269,688	
Liabilities:		
Current liabilities	27,891	
Long-term debt	1,320	
Stockholders' equity	239,996	
Net current assets	238,554	

DECISION DIAGNOSTICS CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Net Sales	561,393	559,004
Cost & expenses	1,250,681	1,078,750
Operating income	(689,287)	(519,746)
Other income (expense), net	(162,359)	(6,000)
Net income	(1,258,379)	(573,155)
Balance for common	(1,258,379)	(573,155)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	138,156,793	113,832,108
Year-end	141,556,392	117,133,349

Consolidated Balance Sheet Items, as of (\$):

	2019	2018
Assets:		
Cash & equivalents	294,113	
Inventories	159,534	
Current assets	1,366,201	
Net property & equip.	802,315	
Total assets	3,903,441	
Liabilities:		
Current liabilities	3,302,195	
Stockholders' equity	356,178	
Net current assets	(1,935,994)	

DEEP DOWN INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	6,300,000	3,706,000
Cost & expenses	6,037,000	4,483,000
Operating income	195,000	(854,000)
Gains or losses	15,000	
Net before taxes	217,000	(845,000)
Income taxes	5,000	5,000
Net income	212,000	(850,000)
Earnings common share		
Primary	\$0.02	\$(0.06)
Fully Diluted	\$0.02	\$(0.06)
Common Shares:		
Full Diluted	13,511,000	13,436,000
Year-end	13,450,680	13,436,243

Consolidated Balance Sheet Items, as of (\$):

	2019	2018
Assets:		
Cash & equivalents	2,816,000	
Current assets	10,772,000	
Net property & equip.	9,328,000	
Total assets	25,912,000	
Liabilities:		
Current liabilities	4,437,000	
Long-term debt	44,000	
Stockholders' equity	17,255,000	
Net current assets	6,335,000	

DESTINATION XL GROUP INC**Earnings, 3 mos. to (Consol. - \$000):**

	05/04/19	05/05/18
Net Sales	112,973	113,331
Cost & expenses	108,873	108,233
Deprec., depl. & amort.	6,338	7,324
Operating income	(2,238)	(2,226)
Net before taxes	(3,102)	(3,112)
Income taxes	(21)	(2)
Net income	(3,081)	(3,110)
Earnings common share		
Primary	\$(0.06)	\$(0.06)
Fully Diluted	\$(0.06)	\$(0.06)
Common Shares:		
Full Diluted	49,602	48,791
Year-end	49,821	48,965

Consolidated Balance Sheet Items, as of (\$000):

	2019	2018
Assets:		
Cash & equivalents	6,783	
Inventories	112,346	
Current assets	134,625	
Net property & equip.	89,477	
Total assets	437,861	
Liabilities:		
Current liabilities	149,931	
Long-term debt	14,771	
Stockholders' equity	61,629	
Net current assets	(15,306)	

DROPBOX INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	385,600	316,300
Cost & expenses	406,900	782,200
Operating income	(21,300)	(465,900)
Other income (expense), net	4,200	3,400
Net before taxes	(13,400)	(463,700)
Income taxes	(5,700)	1,800
Net income	(7,700)	(465,500)
Earnings common share		
Primary	\$(0.02)	\$(2.13)
Fully Diluted	\$(0.02)	\$(2.13)
Common Shares:		
Full Diluted	410,500	218,800

	Year-end	411,400	400,397

Consolidated Balance Sheet Items, as of (\$000):

	2019	2018
Assets:		
Cash & equivalents	915,200	
Current assets	1,007,600	
Net property & equip.	340,900	
Total assets	2,128,600	
Liabilities:		
Current liabilities	865,800	
Long-term debt	106,700	
Stockholders' equity	704,900	
Net current assets	141,800	

ELECTROCORE INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Net Sales	409,601	81,187
Cost & expenses	14,620,613	9,180,097
Operating income	(14,211,012)	(9,098,910)
Other income (expense), net	349,482	(344,625)
Net income	(13,861,530)	(9,443,535)
Earnings common share		
Primary	\$(0.47)	\$(0.47)
Fully Diluted	\$(0.47)	\$(0.47)
Common Shares:		
Full Diluted	29,319,318	
Year-end	29,633,240	218,982,140

Consolidated Balance Sheet Items, as of (\$):

	2019	2018
Assets:		
Cash & equivalents	6,953,786	
Inventories	3,589,264	
Current assets	57,238,830	
Net property & equip.	392,029	
Total assets	62,499,617	
Liabilities:		
Current liabilities	5,329,791	
Stockholders' equity	52,532,998	
Net current assets	51,909,039	

ELECTRONIC ARTS, INC.**Annual Report****Consolidated Income Statement, Years Ended Mar. 31****(\$000):**

	2019	2018	2017
			(revised)
Product revenue	1,593,000	2,586,000	2,640,000
Service & other revenue	3,357,000	2,564,000	2,205,000
Total net revenue	4,950,000	5,150,000	4,845,000
Cost of revenue:			
product	517,000	822,000	893,000
service & other	805,000	455,000	405,000
Total cost of revenue	1,322,000	1,277,000	1,298,000
Gross profit	3,628,000	3,873,000	3,547,000
Research & development expense	1,433,000	1,320,000	1,205,000
Marketing & sales expense	702,000	641,000	673,000
General & administrative expense	460,000	469,000	439,000
Acquisition-related contingent consideration	14,000		
Amortization of intangibles	23,000	9,000	6,000
Total operating expenses	2,632,000	2,439,000	2,323,000
Operating income (loss)	996,000	1,434,000	1,224,000
Amortization of debt discount	1,000		2,000
Amortization of debt issuance costs	2,000	2,000	2,000
Coupon interest expense	41,000	42,000	42,000
Other interest expense	1,000		1,000
Interest expense	45,000	44,000	47,000
Interest income	88,000	50,000	25,000
Net gain (loss) on foreign currency			

transactions	(9,000)	18,000	(40,000)
Net gain (loss) on foreign currency forward contracts	50,000	(16,000)	46,000
Other income (expense), net	(1,000)	7,000	2,000
Income (loss) before provision for (benefit from) income taxes - domestic	170,000	440,000	382,000
Income (loss) before provision for (benefit from) income taxes - foreign	909,000	1,009,000	828,000
Income (loss) before provision for (benefit from) income tax expense	1,079,000	1,449,000	1,210,000
Current federal income tax expense (benefit)	29,000	138,000	86,000
Current state income tax expense (benefit)	5,000	4,000	3,000
Current foreign income tax expense (benefit)	42,000	61,000	51,000
Total current income tax expense (benefit)	76,000	203,000	140,000
Deferred federal income tax expense (benefit)	(18,000)	197,000	96,000
Deferred state income tax expense (benefit)	...	9,000	9,000
Deferred foreign income tax expense (benefit)	2,000	(3,000)	(2,000)
Total deferred income tax expense (benefit)	(16,000)	203,000	103,000
Provision for (benefit from) income taxes	60,000	406,000	243,000
Net income (loss)	1,019,000	1,043,000	967,000
Weighted average shares outstanding - basic	303,000	308,000	303,000
Weighted average shares outstanding - diluted	306,000	312,000	314,000
Year end shares outstanding	298,000	306,370	308,367
Net income (loss) per share - basic	\$3.36	\$3.39	\$3.19
Net income (loss) per share - diluted	\$3.33	\$3.34	\$3.08
Number of full time employees	9,700	9,300	8,800
Number of common stockholders	849	1,159	1,230
Foreign currency translation adjustments	...	18,000	(17,000)

□ Reclassified to conform with 2018 presentation; □ As is; □ Approximately; □ As of May 20, 2019; □ As of May 21, 2018; □ As of May 22, 2017

Consolidated Balance Sheet, Years Ended Mar. 31 (\$000):

	2019	2018
Cash & cash equivalents	4,708,000	4,258,000
Short-term investments	737,000	1,073,000
Receivables, gross	630,000	550,000
Allowances	7,000	165,000
Receivables, net	623,000	385,000
Other current assets	313,000	288,000
Total current assets	6,381,000	6,004,000
Computer equipment & software	710,000	744,000

Buildings	343,000	336,000
Leasehold improvements	139,000	139,000
Equipment, furniture & fixtures & other property & equipment	80,000	84,000
Land	66,000	66,000
Construction in progress	21,000	7,000
Gross property & equipment	1,359,000	1,376,000
Less: accumulated depreciation	911,000	923,000
Property & equipment, net	448,000	453,000
Goodwill	1,892,000	1,883,000
Acquisition-related intangibles, net	87,000	71,000
Deferred income taxes, net	35,000	84,000
Other assets	114,000	89,000
Total assets	8,957,000	8,584,000
Accounts payable	113,000	48,000
Accrued compensation & benefits	238,000	282,000
Other accrued expenses	290,000	260,000
Accrued royalties	144,000	171,000
Sales return & price protection reserves	150,000	...
Contingent consideration	136,000	...
Deferred net revenue (other)	94,000	108,000
Deferred net revenue (online-enabled games)	1,100,000	1,622,000
Total current liabilities	2,265,000	2,491,000
Senior notes, net	994,000	992,000
Income tax obligations	233,000	250,000
Deferred income taxes, net	2,000	1,000
Other liabilities	132,000	255,000
Total liabilities	3,626,000	3,989,000
Common stock	3,000	3,000
Additional paid-in capital	...	657,000
Retained earnings (accumulated deficit)	5,358,000	4,062,000
Unrealized gains (losses) on available-for-sale securities	(1,000)	(8,000)
Unrealized gains (losses) on derivative instruments	22,000	(89,000)
Foreign currency translation adjustments	(51,000)	(30,000)
Accumulated other comprehensive income (loss)	(30,000)	(127,000)
Total stockholders' equity	5,331,000	4,595,000

Recent Dividends:

1. **Electronic Arts, Inc. common.**
No dividends paid.

Annual Dividends:

1. **Electronic Arts, Inc. common.**
No dividends paid.

ENGLOBAL CORP.

Earnings, 3 mos. to (Consol. - \$):

	03/30/19	03/31/18
Total Revenues	12,163,000	13,188,000
Cost & expenses	13,129,000	14,357,000
Operating income	(966,000)	(1,169,000)
Interest expense	3,000	9,000
Other income (expense), net	15,000	(5,000)
Net before taxes	(954,000)	(1,183,000)
Income taxes	20,000	17,000
Net income	(974,000)	(1,200,000)
Earnings common share		
Primary	\$(0.04)	\$(0.04)
Fully Diluted	\$(0.04)	\$(0.04)
Common Shares:		
Full Diluted	27,431,000	27,514,000
Year-end	27,409,907	27,514,380

Consolidated Balance Sheet Items, as of (\$):

	2019
Assets:	
Cash & equivalents	7,297,000

Current assets	20,456,000
Net property & equip.	610,000
Total assets	23,482,000
Liabilities:	
Current liabilities	8,119,000
Stockholders' equity	14,471,000
Net current assets	12,337,000

ENTASIS THERAPEUTICS HOLDINGS INC

Earnings, 3 mos. to Mar 31 (Consol. - \$000):

	2019	2018
Cost & expenses	14,191	11,768
Operating income	(14,191)	(11,768)
Interest income	492	12
Other income (expense), net	829	1,089
Net before taxes	(12,870)	...
Income taxes	71	...
Net income	(12,941)	(10,667)
Earnings common share		
Primary	\$(0.99)	\$(844.01)
Fully Diluted	\$(0.99)	\$(844.01)
Common Shares:		
Full Diluted	13,127	13
Year-end	13,127	13

Consolidated Balance Sheet Items, as of (\$000):

	2019
Assets:	
Cash & equivalents	13,535
Current assets	78,876
Net property & equip.	379
Total assets	81,267
Liabilities:	
Current liabilities	8,976
Stockholders' equity	70,574
Net current assets	69,900

EQUILLIUM INC

Earnings, 3 mos. to Mar 31 (Consol. - \$):

	2019	2018
Cost & expenses	6,348,000	1,037,000
Operating income	(6,348,000)	(1,037,000)
Interest income	398,000	5,000
Interest expense	...	489,000
Other income (expense), net	...	(56,000)
Net income	(5,950,000)	(1,577,000)
Earnings common share		
Primary	\$(0.34)	\$(0.15)
Fully Diluted	\$(0.34)	\$(0.15)
Common Shares:		
Full Diluted	17,376,236	10,708,074
Year-end	17,376,236	10,708,074

Consolidated Balance Sheet Items, as of (\$):

	2019
Assets:	
Cash & equivalents	21,394,000
Current assets	62,629,000
Net property & equip.	83,000
Total assets	62,727,000
Liabilities:	
Current liabilities	3,052,000
Stockholders' equity	59,494,000
Net current assets	59,577,000

EVERQUOTE INC

Earnings, 3 mos. to Mar 31 (Consol. - \$000):

	2019	2018
Total Revenues	52,233	40,730
Cost & expenses	56,799	41,965
Operating income	(4,566)	(1,235)
Interest income	184	...
Interest expense	...	93
Net income	(4,382)	(1,328)
Balance for common	(4,382)	(12,341)
Earnings common share		
Primary	\$(0.17)	\$(1.42)
Fully Diluted	\$(0.17)	\$(1.42)
Common Shares:		
Full Diluted	25,294	8,707
Year-end	25,439	9,082

Consolidated Balance Sheet Items, as of (\$000):

	2019
Assets:	
Cash & equivalents	37,719
Current assets	64,873
Net property & equip.	4,673
Total assets	70,255

Liabilities:		
Current liabilities	27,266	
Stockholders' equity	41,786	
Net current assets	37,607	

EXP WORLD HOLDINGS INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	157,033,632	61,962,531
Cost & expenses	163,132,027	72,628,426
Operating income	(6,098,395)	(10,665,895)
Other income (expense), net	(80,976)	
Net before taxes	(6,133,126)	(10,665,895)
Income taxes	162,697	30,450
Net income	(6,295,823)	(10,696,345)
Earnings common share		
Primary	\$(0.10)	\$(0.19)
Fully Diluted	\$(0.10)	\$(0.19)
Common Shares:		
Full Diluted	60,749,378	56,193,753
Year-end	61,499,843	56,303,864

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	20,771,971	
Current assets	56,452,170	
Net property & equip.	3,153,814	
Total assets	70,604,458	
Liabilities:		
Current liabilities	37,313,013	
Long-term debt	1,716,853	
Stockholders' equity	31,362,378	
Net current assets	19,139,157	

FIBROCELL SCIENCE INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Cost & expenses	3,857,000	2,981,000
Operating income	(3,857,000)	(2,981,000)
Interest expense	197,000	190,000
Other income (expense), net	388,000	270,000
Net income	(3,666,000)	(2,901,000)
Balance for common	(3,891,000)	(3,104,000)
Earnings common share		
Primary	\$(0.40)	\$(0.55)
Fully Diluted	\$(0.40)	\$(0.55)
Common Shares:		
Full Diluted	9,758,332	5,672,976
Year-end	9,758,332	5,671,270

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	11,322,000	
Current assets	12,539,000	
Net property & equip.	1,183,000	
Total assets	18,135,000	
Liabilities:		
Current liabilities	3,489,000	
Stockholders' equity	6,003,000	
Net current assets	9,050,000	

FORESCOUT TECHNOLOGIES INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	75,568	59,697
Cost & expenses	109,633	87,184
Operating income	(34,065)	(27,487)
Interest expense	93	243
Other income (expense), net	617	662
Net before taxes	(33,541)	(27,068)
Income taxes	711	1,128
Net income	(34,252)	(28,196)
Earnings common share		
Primary	\$(0.78)	\$(0.74)
Common Shares:		
Year-end	45,133	39,214

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	70,663	
Inventories	1,248	
Current assets	210,095	
Net property & equip.	23,900	
Total assets	393,673	
Liabilities:		
Current liabilities	169,766	

Long-term debt	6,402	
Stockholders' equity	114,929	
Net current assets	40,329	

FORTRESS BIOTECH INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	6,477	5,903
Cost & expenses	39,085	40,075
Operating income	(32,608)	(34,172)
Interest income	438	278
Interest expense	2,469	2,403
Other income (expense), net	18,384	155
Income discount oper.	(2,076)	(2,076)
Net income	(16,255)	(38,218)
Balance for common	1,392	(21,018)
Earnings common share		
Primary	\$0.03	\$(0.49)
Fully Diluted	\$0.02	\$(0.49)
Common Shares:		
Full Diluted	63,811	42,518
Year-end	63,602	52,687

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	116,444	
Inventories	629	
Current assets	136,549	
Net property & equip.	11,833	
Total assets	200,538	
Liabilities:		
Current liabilities	48,957	
Long-term debt	73,607	
Stockholders' equity	20,817	
Net current assets	87,592	

FORTY SEVEN INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Cost & expenses	23,710	14,996
Operating income	(23,710)	(14,996)
Other income (expense), net	694	221
Net income	(23,016)	(14,775)
Earnings common share		
Primary	\$(0.74)	\$(2.24)
Fully Diluted	\$(0.74)	\$(2.24)
Common Shares:		
Full Diluted	31,166	6,600
Year-end	31,299	6,709

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	15,544	
Current assets	124,864	
Net property & equip.	1,244	
Total assets	130,311	
Liabilities:		
Current liabilities	15,456	
Long-term debt	1,588	
Stockholders' equity	112,899	
Net current assets	109,408	

FULGENT GENETICS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	5,370	4,653
Cost & expenses	7,193	6,847
Operating income	(1,823)	(2,194)
Equity earnings	279	245
Net before taxes	(1,616)	(2,099)
Income taxes	13	(434)
Net income	(1,908)	(1,910)
Earnings common share		
Primary	\$(0.10)	\$(0.11)
Fully Diluted	\$(0.10)	\$(0.11)
Common Shares:		
Full Diluted	18,228	17,864
Year-end	18,286	17,876

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	29,427	
Current assets	36,301	
Net property & equip.	6,046	
Total assets	55,652	
Liabilities:		

Current liabilities	3,203	
Stockholders' equity	49,961	
Net current assets	33,098	

G1 THERAPEUTICS INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Cost & expenses	25,881,000	20,725,000
Operating income	(25,881,000)	(20,725,000)
Other income (expense), net	1,929,000	315,000
Net income	(23,952,000)	(20,410,000)
Balance for common	(23,952,000)	(20,410,000)
Earnings common share		
Primary	\$(0.64)	\$(0.70)
Fully Diluted	\$(0.64)	\$(0.70)
Common Shares:		
Full Diluted	37,396,980	29,360,470
Year-end	37,461,016	32,684,885

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	347,797,000	
Current assets	348,884,000	
Net property & equip.	1,343,000	
Total assets	351,675,000	
Liabilities:		
Current liabilities	11,549,000	
Stockholders' equity	338,941,000	
Net current assets	337,335,000	

GCI LIBERTY INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	217,736	61,204
Cost & expenses	182,702	52,552
Deprec., depl. & amort.	67,678	16,021
Operating income	(32,644)	(7,369)
Other income (expense), net	8,553	(7,678)
Gains or losses	1,009,600	(71,481)
Net before taxes	947,891	(94,776)
Income taxes	269,405	75,955
Net income	678,486	(170,731)
Earnings common share		
Primary	\$6.47	\$(1.58)
Fully Diluted	\$6.41	\$(1.58)
Common Shares:		
Full Diluted	105,864	107,735
Year-end	105,519	109,005

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	422,420	
Current assets	669,375	
Net property & equip.	1,161,345	
Total assets	9,818,260	
Liabilities:		
Current liabilities	1,172,962	
Long-term debt	2,160,197	
Stockholders' equity	4,939,472	
Net current assets	(503,587)	

GENERAL FINANCE CORP

Earnings, 9 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	281,994,000	253,468,000
Net Sales	100,594,000	95,030,000
Cost & expenses	203,971,000	192,219,000
Deprec., depl. & amort.	31,952,000	29,671,000
Operating income	46,071,000	31,578,000
Interest income	108,000	81,000
Interest expense	27,700,000	24,667,000
Other income (expense), net	(26,125,000)	(4,906,000)
Net before taxes	(7,646,000)	2,086,000
Income taxes	5,056,000	519,000
Net income	(12,702,000)	1,567,000
Balance for common	(15,468,000)	(398,000)
Earnings common share		
Primary	\$(0.53)	\$(0.02)
Fully Diluted	\$(0.53)	\$(0.02)
Common Shares:		
Full Diluted	29,084,947	26,210,697
Year-end	30,341,321	26,753,254

GLOWPOINT INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	2,594,000	3,474,000
Cost & expenses	3,033,000	4,122,000
Operating income	(598,000)	(880,000)
Net income	(598,000)	(1,285,000)
Balance for common	(613,000)	(1,288,000)
Earnings common share		
Primary	\$(0.12)	\$(0.28)
Fully Diluted	\$(0.12)	\$(0.28)
Common Shares:		
Full Diluted	5,104,000	4,623,000
Year-end	5,040,500	4,648,500

Consolidated Balance Sheet Items, as of (\$):

Assets:		2019
Cash & equivalents		1,589,000
Current assets		3,650,000
Net property & equip.		610,000
Total assets		7,611,000
Liabilities:		
Current liabilities		1,366,000
Stockholders' equity		6,245,000
Net current assets		2,284,000

GOSSAMER BIO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	34,017	26,126
Operating income	(34,017)	(26,126)
Interest income	1,049	89
Interest expense	19	
Other income (expense), net	376	
Net income	(32,611)	(26,037)
Earnings common share		
Primary	\$(0.90)	\$(4.49)
Fully Diluted	\$(0.90)	\$(4.49)
Common Shares:		
Full Diluted	36,317,230	5,797,693
Year-end	60,029,470	5,681,722

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		170,847
Current assets		497,788
Net property & equip.		4,110
Total assets		515,949
Liabilities:		
Current liabilities		25,152
Stockholders' equity		480,260
Net current assets		472,636

GREEN PLAINS PARTNERS LP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	21,087	25,885
Cost & expenses	7,982	9,811
Operating income	12,120	14,893
Interest income	20	20
Interest expense	2,055	1,571
Other income (expense), net		75
Equity earnings	(215)	13
Net before taxes	10,085	13,417
Income taxes	52	32
Net income	10,248	13,372
Earnings common share		
Primary	\$0.43	\$0.41
Fully Diluted	\$0.43	\$0.41
Common Shares:		
Full Diluted	23,119	15,922
Year-end	23,138	31,812

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		304
Current assets		21,894
Net property & equip.		39,926
Total assets		121,400
Liabilities:		
Current liabilities		24,844
Long-term debt		143,037
Net current assets		(2,950)

GREENLANE HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Net Sales	49,897,604	43,257,643
Cost & expenses	54,377,068	40,685,944
Operating income	(5,163,541)	2,329,290
Interest expense	601,880	42,259
Other income (expense), net	(11,887,263)	93,515
Net before taxes	(17,652,684)	2,380,546
Income taxes	11,665	81,817
Net income	(17,664,349)	2,298,729
Earnings common share		
Common Shares:		

Consolidated Balance Sheet Items, as of (\$):

Assets:		2019
Cash & equivalents		2,776,775
Inventories		36,073,121
Current assets		63,145,196
Net property & equip.		12,727,827
Total assets		93,746,779
Liabilities:		
Current liabilities		35,113,538
Long-term debt		68,449,398
Stockholders' equity		(28,083,222)
Net current assets		28,031,658

GREENSKY INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	103,700	85,326
Cost & expenses	90,745	60,779
Operating income	6,841	19,306
Interest income	1,596	1,320
Interest expense	6,243	5,591
Gains or losses	(35)	(702)
Net before taxes	6,806	
Income taxes	(595)	
Net income	7,401	18,604
Earnings common share		
Primary	\$0.05	\$0.05
Fully Diluted	\$0.05	\$0.05
Common Shares:		
Full Diluted		13,689
Year-end		181,339

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		267,798
Current assets		462,855
Net property & equip.		12,156
Total assets		832,725
Liabilities:		
Current liabilities		179,369
Long-term debt		386,243
Stockholders' equity		(73,260)
Net current assets		283,486

GRITSTONE ONCOLOGY INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	20,276	13,439
Operating income	(18,929)	(13,439)
Interest income	920	63
Net income	(18,009)	(13,376)
Earnings common share		
Primary	\$(0.62)	\$(6.03)
Fully Diluted	\$(0.62)	\$(6.03)
Common Shares:		
Full Diluted	28,939	2,218
Year-end	29,024	2,264

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		34,572
Current assets		135,000
Net property & equip.		15,652
Total assets		175,487
Liabilities:		
Current liabilities		14,112
Stockholders' equity		132,222
Net current assets		120,888

GUARDANT HEALTH INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	36,655	16,692
Cost & expenses	60,319	35,339

Operating income	(23,664)	(18,647)
Interest income	2,485	985
Interest expense	293	331
Other income (expense), net	147	4,149
Net before taxes	(21,325)	
Income taxes	26	
Net income	(21,351)	(13,844)

Earnings common share

Primary	\$(0.30)	\$(1.16)
Fully Diluted	\$(0.30)	\$(1.16)

Common Shares:

Full Diluted	85,935	11,920
Year-end	86,098	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		153,790
Inventories		10,256
Current assets		512,255
Net property & equip.		30,581
Total assets		579,171
Liabilities:		
Current liabilities		48,192
Long-term debt		100
Stockholders' equity		468,134
Net current assets		464,063

GUARDANT HEALTH INC

Secondary Offering On May 22, 2019, Co. announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of \$71.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Co. In addition, Co. has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Co., were expected to be \$319,500,000, excluding any exercise of the underwriters' option to purchase additional shares. The offering was expected to close on May 28, 2019, subject to customary closing conditions.

GULF RESOURCES INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	38,570	2,247,267
Cost & expenses	6,434,600	10,544,247
Operating income	(6,396,030)	(8,296,980)
Interest income	135,579	169,478
Interest expense	38,824	43,344
Net before taxes	(6,299,275)	(8,170,846)
Income taxes	(1,395,137)	(1,193,746)
Net income	(4,904,138)	(6,977,100)
Earnings common share		
Primary	\$(0.10)	\$(0.15)
Fully Diluted	\$(0.10)	\$(0.15)
Common Shares:		
Full Diluted	46,886,558	46,826,388
Year-end	46,920,760	46,803,791

Consolidated Balance Sheet Items, as of (\$):

Assets:		2019
Cash & equivalents		179,653,141
Current assets		181,254,692
Net property & equip.		89,963,658
Total assets		310,979,618
Liabilities:		
Current liabilities		5,197,347
Long-term debt		2,109,459
Stockholders' equity		295,137,216
Net current assets		176,057,345

HARPOON THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	1,063	1,563
Cost & expenses	15,214	6,515
Operating income	(14,151)	(4,952)
Interest income	532	73
Other income (expense), net	40	(2)
Net income	(13,579)	(4,881)
Earnings common share		
Primary	\$(0.92)	\$(5.04)
Fully Diluted	\$(0.92)	\$(5.04)
Common Shares:		
Full Diluted	14,750	969

Year-end	24,352	
Consolidated Balance Sheet Items, as of (\$000):		
Assets:		
Cash & equivalents	95,926	2019
Current assets	140,653	
Net property & equip.	5,502	
Total assets	166,932	
Liabilities:		
Current liabilities	11,897	
Stockholders' equity	133,594	
Net current assets	128,756	

HAWKINS INC

Dividend Announcement On May 23, 2019, Co.'s Board of Directors has declared a quarterly cash dividend of \$0.23 per share, payable June 21, 2019, to shareholders of record at the close of business on June 7, 2019.

HELIUS MEDICAL TECHNOLOGIES INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Cost & expenses	7,498,000	4,717,000
Operating income	(6,821,000)	(4,717,000)
Other income (expense), net	8,300,000	2,584,000
Foreign currency	(155,000)	968,000
Net income	1,324,000	(1,165,000)
Earnings common share		
Primary	\$0.05	\$(0.06)
Fully Diluted	\$(0.06)	\$(0.08)
Common Shares:		
Full Diluted	26,785,708	20,460,656
Year-end	25,844,180	20,797,309

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	18,656,000	2019
Inventories	731,000	
Current assets	20,831,000	
Net property & equip.	693,000	
Total assets	22,498,000	
Liabilities:		
Current liabilities	9,883,000	
Stockholders' equity	12,018,000	
Net current assets	10,948,000	

HIGHPOWER INTERNATIONAL INC.

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Net Sales	58,113,480	49,783,453
Cost & expenses	57,306,906	51,883,562
Operating income	806,574	(2,100,109)
Interest expense	470,423	241,852
Other income (expense), net	257,029	1,213,346
Net before taxes	593,180	(1,128,615)
Income taxes	285,459	(9,679)
Net income	307,721	(1,118,936)
Earnings common share		
Primary	\$0.02	\$(0.07)
Fully Diluted	\$0.02	\$(0.07)
Common Shares:		
Full Diluted	15,604,907	15,509,658
Year-end	15,567,953	15,509,658

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	24,167,300	2019
Inventories	58,456,282	
Current assets	194,870,224	
Net property & equip.	68,148,472	
Total assets	284,104,140	
Liabilities:		
Current liabilities	201,080,037	
Stockholders' equity	79,474,052	
Net current assets	(6,209,813)	

HOMOLOGY MEDICINES INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Cost & expenses	25,393,000	11,825,000
Operating income	(25,123,000)	(10,696,000)
Interest income	1,271,000	479,000
Net income	(23,852,000)	(10,217,000)
Earnings common share		
Primary	\$(0.64)	\$(4.09)
Fully Diluted	\$(0.64)	\$(4.09)
Common Shares:		

Full Diluted	37,384,507	2,500,178
Year-end	37,437,297	
Consolidated Balance Sheet Items, as of (\$):		
Assets:		
Cash & equivalents	40,839,000	2019
Current assets	190,502,000	
Net property & equip.	40,984,000	
Total assets	233,026,000	
Liabilities:		
Current liabilities	17,647,000	
Stockholders' equity	174,264,000	
Net current assets	172,855,000	

I.D. SYSTEMS, INC. (DE)

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	13,611,000	13,379,000
Cost & expenses	15,812,000	14,356,000
Operating income	(2,201,000)	(977,000)
Interest income	65,000	77,000
Interest expense	20,000	57,000
Other income (expense), net	(38,000)	(33,000)
Net income	(2,194,000)	(990,000)
Earnings common share		
Primary	\$(0.12)	\$(0.06)
Fully Diluted	\$(0.12)	\$(0.06)
Common Shares:		
Full Diluted	17,621,000	16,981,000
Year-end	18,214,000	17,635,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	9,515,000	2019
Inventories	5,058,000	
Current assets	36,223,000	
Net property & equip.	2,194,000	
Total assets	62,529,000	
Liabilities:		
Current liabilities	21,321,000	
Stockholders' equity	29,732,000	
Net current assets	14,902,000	

I3 VERTICALS INC

Earnings, 6 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	170,262	154,920
Cost & expenses	159,485	143,100
Operating income	3,327	5,944
Interest expense	2,069	5,006
Other income (expense), net	(8,245)	(8,245)
Net before taxes	1,258	(7,307)
Income taxes	129	(139)
Net income	1,129	(7,168)
Earnings common share		
Primary	\$(0.10)	\$(0.10)
Fully Diluted	\$(0.10)	\$(0.10)
Common Shares:		
Full Diluted	8,849	
Year-end	26,304	23,897

INNODATA INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	13,694,000	14,120,000
Cost & expenses	14,173,000	13,814,000
Operating income	(479,000)	306,000
Net before taxes	(479,000)	306,000
Income taxes	(28,000)	582,000
Net income	(451,000)	(276,000)
Earnings common share		
Primary	\$0.02	\$(0.01)
Fully Diluted	\$0.02	\$(0.01)
Common Shares:		
Full Diluted	25,927,000	25,878,000
Year-end	25,952,000	25,878,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	12,161,000	2019
Current assets	25,728,000	
Net property & equip.	6,860,000	
Total assets	52,680,000	
Liabilities:		
Current liabilities	14,600,000	
Long-term debt	(601,000)	

Stockholders' equity	30,471,000
Net current assets	11,128,000

INNOVATIVE SOLUTIONS AND SUPPORT INC

New Accountant On May 8, 2019, KPMG LLP resigned as Co.'s independent public accounting firm. Also on May 24, 2019, Co. engaged PricewaterhouseCoopers LLP as its new independent public accounting firm.

INNOVATIVE SOLUTIONS AND SUPPORT INC

Earnings, 6 mos. to Mar 31(Consol. - \$):

	2019	2018
Net Sales	8,180,777	6,815,188
Cost & expenses	7,911,695	9,010,260
Operating income	269,082	(2,195,072)
Other income (expense), net	32,600	37,096
Net before taxes	349,714	(2,136,671)
Income taxes	7,794	61,819
Net income	341,920	(2,198,490)
Earnings common share		
Primary	\$0.02	\$(0.13)
Fully Diluted	\$0.02	\$(0.13)
Common Shares:		
Full Diluted	16,858,160	16,791,687
Year-end	16,909,036	16,840,599

INSMED INC

Secondary Offering On May 21, 2019, Co. announced that it priced a registered underwritten public offering of 9,615,385 shares of its common stock, at a price to the public of \$26.00 per share before underwriting discounts and commissions. Gross proceeds from the offering of these shares, before deducting underwriting discounts and commissions, were expected to be approximately \$250,000,000. The underwriters have been granted 30-day options to purchase up to an additional 1,042,307 shares of common stock from Co. and up to 400,000 shares of common stock from William H. Lewis, Co.'s Chairman and Chief Executive Officer.

INTEGRITY APPLICATIONS INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	25,562	28,209
Cost & expenses	1,050,615	1,938,018
Operating income	(1,025,053)	(1,909,809)
Other income (expense), net	(523)	78,858
Foreign currency	8,063	(13,627)
Net income	(1,021,653)	(1,847,794)
Balance for common		
	(1,021,653)	(2,356,386)
Earnings common share		
Primary	\$(0.01)	\$(0.34)
Fully Diluted	\$(0.01)	\$(0.34)
Common Shares:		
Full Diluted	143,615,503	7,021,533
Year-end	146,440,814	7,469,604

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	30,576	2019
Inventories	157,344	
Current assets	261,918	
Net property & equip.	147,435	
Total assets	839,102	
Liabilities:		
Current liabilities	3,096,051	
Long-term debt	174,117	
Stockholders' equity	(2,686,348)	
Net current assets	(2,834,133)	

INTELGENX TECHNOLOGIES CORP

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	416,000	239,000
Cost & expenses	2,564,000	2,077,000
Operating income	(2,319,000)	(2,021,000)
Net income	(2,588,000)	(2,264,000)
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	93,519,140	67,404,467
Year-end	93,527,473	67,731,467

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	6,627,000
Inventories	383,000
Current assets	10,602,000
Net property & equip.	6,279,000
Total assets	18,325,000
Liabilities:	
Current liabilities	2,597,000
Long-term debt	7,332,000
Stockholders' equity	7,802,000
Net current assets	8,005,000

INTERMOLECULAR INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	6,651	9,675
Cost & expenses	9,192	10,490
Operating income	(2,541)	(815)
Other income (expense), net	96	87
Net before taxes	(622)	(622)
Income taxes	1	1
Net income	(2,262)	(623)
Earnings common share		
Primary	\$(0.05)	\$(0.01)
Fully Diluted	\$(0.05)	\$(0.01)
Common Shares:		
Full Diluted	49,758	49,582
Year-end	49,758	49,601

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	3,816
Current assets	30,832
Net property & equip.	3,125
Total assets	50,207
Liabilities:	
Current liabilities	5,275
Stockholders' equity	32,625
Net current assets	25,557

INTERNATIONAL ISOTOPES INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Cost & expenses	2,385,295	2,651,421
Operating income	142,557	149,605
Interest income	3,422	1,307
Interest expense	114,077	106,034
Other income (expense), net	24,632	53,362
Net income	56,534	98,240
Earnings common share		
Common Shares:		
Full Diluted	413,906,700	526,418,051
Year-end	416,912,686	409,922,096

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	398,604
Inventories	3,086,126
Current assets	5,128,899
Net property & equip.	1,885,914
Total assets	14,115,760
Liabilities:	
Current liabilities	7,263,462
Long-term debt	471,773
Stockholders' equity	(1,384,401)
Net current assets	(2,134,563)

INTRICON CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	30,109,000	25,363,000
Cost & expenses	29,284,000	24,011,000
Operating income	825,000	1,352,000
Interest expense	(215,000)	188,000
Other income (expense), net	(134,000)	(208,000)
Net before taxes	906,000	956,000
Income taxes	131,000	187,000
Net income	775,000	769,000
Earnings common share		
Primary	\$0.09	\$0.11
Fully Diluted	\$0.08	\$0.10
Common Shares:		
Full Diluted	9,382,000	7,843,000
Year-end	8,714,000	6,944,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Inventories	19,134,000
Current assets	66,686,000
Net property & equip.	12,261,000
Total assets	120,896,000
Liabilities:	
Current liabilities	21,305,000
Stockholders' equity	93,314,000
Net current assets	45,381,000

INTUIT INC**Earnings, 9 mos. to Apr 30(Consol. - \$000):**

	2019	2018
Total Revenues	5,790,000	5,161,000
Cost & expenses	3,779,000	3,397,000
Operating income	2,007,000	1,760,000
Gains or losses	2,000	4,000
Net before taxes	2,018,000	1,759,000
Income taxes	417,000	392,000
Net income	1,601,000	1,367,000
Earnings common share		
Primary	\$6.16	\$5.34
Fully Diluted	\$6.06	\$5.25
Common Shares:		
Full Diluted	264,000	260,000
Year-end	259,334	256,574

INVO BIOSCIENCE, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	189,432	104,140
Cost & expenses	538,543	244,423
Operating income	(349,111)	(140,283)
Net income	(458,570)	(144,723)
Earnings common share		
Common Shares:		
Full Diluted	154,102,856	143,340,969
Year-end	154,621,112	143,994,700

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	3,057,466
Inventories	51,685
Current assets	3,410,564
Net property & equip.	81,709
Total assets	3,503,231
Liabilities:	
Current liabilities	6,605,701
Stockholders' equity	(3,102,470)
Net current assets	(3,195,137)

JOINT CORP (NEW)**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	10,679,376	8,646,964
Cost & expenses	9,264,833	8,343,322
Deprec., depl. & amort.	365,678	387,417
Operating income	1,048,865	(83,775)
Other income (expense), net	(116,838)	(11,194)
Gains or losses	19,298	
Net before taxes	951,325	(94,969)
Income taxes	(1,319)	(63,355)
Net income	952,644	(31,614)
Balance for common	952,644	(31,614)
Earnings common share		
Primary	\$0.07	\$0.07
Fully Diluted	\$0.07	\$0.07
Common Shares:		
Full Diluted	14,256,006	13,587,837
Year-end	13,785,334	13,593,754

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	8,086,426
Current assets	10,904,453
Net property & equip.	4,211,550
Total assets	33,939,717
Liabilities:	
Current liabilities	10,863,879
Long-term debt	52,812
Stockholders' equity	2,072,360
Net current assets	40,574

KALA PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

Cost & expenses	25,436	11,139
Operating income	(24,050)	(11,139)
Interest income	756	209
Interest expense	2,094	367
Net income	(25,388)	(11,297)
Earnings common share		
Primary	\$(0.75)	\$(0.46)
Fully Diluted	\$(0.75)	\$(0.46)
Common Shares:		
Full Diluted	33,878	24,542
Year-end	33,883	24,556

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	138,944
Inventories	5,415
Current assets	150,449
Net property & equip.	2,849
Total assets	197,016
Liabilities:	
Current liabilities	14,602
Long-term debt	70,457
Stockholders' equity	82,367
Net current assets	135,847

KEMPHARM INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	11,369	14,769
Operating income	(11,369)	(14,769)
Other income (expense), net	453	(9,741)
Net before taxes	(12,299)	(26,227)
Income taxes	(8)	(8)
Net income	(12,291)	(26,219)
Earnings common share		
Primary	\$(0.46)	\$(1.77)
Fully Diluted	\$(0.46)	\$(1.77)
Common Shares:		
Full Diluted	26,702	14,792
Year-end	27,977	15,105

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	13,438
Current assets	15,311
Net property & equip.	1,688
Total assets	19,867
Liabilities:	
Current liabilities	15,172
Long-term debt	75,373
Stockholders' equity	(74,836)
Net current assets	139

KODIAK SCIENCES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	8,460	5,547
Operating income	(8,460)	(5,547)
Interest income	480	48
Interest expense	4	1,470
Other income (expense), net		(1,951)
Net income	(7,984)	(8,920)
Balance for common	(7,984)	(8,920)
Earnings common share		
Primary	\$(0.21)	\$(1.16)
Fully Diluted	\$(0.21)	\$(1.16)
Common Shares:		
Full Diluted	37,248	7,684
Year-end	36,910	7,937

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	57,222
Current assets	83,277
Net property & equip.	1,084
Total assets	87,077
Liabilities:	
Current liabilities	4,773
Stockholders' equity	80,095
Net current assets	78,504

LEAP THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	8,795	6,344
Operating income	(8,795)	(6,344)
Interest income	82	77
Other income (expense), net	75	(4,205)
Foreign currency	42	(144)
Net income	(8,603)	(10,622)
Balance for common	(8,962)	(10,622)
Earnings common share		
Primary	\$(0.47)	\$(0.85)
Fully Diluted	\$(0.47)	\$(0.85)
Common Shares:		
Full Diluted	19,237	12,449
Year-end	22,260	14,501
Consolidated Balance Sheet Items, as of (\$000):		
Assets:		2019
Cash & equivalents	21,709	21,709
Current assets	22,712	22,712
Net property & equip.	74	74
Total assets	26,083	26,083
Liabilities:		
Current liabilities	8,186	8,186
Stockholders' equity	17,064	17,064
Net current assets	14,526	14,526

LEGACY RESERVES INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	118,497,000	137,479,000
Cost & expenses	78,588,000	58,988,000
Deprec., depl. & amort.	42,549,000	36,547,000
Operating income	(2,640,000)	41,944,000
Interest income	6,000	12,000
Other income (expense), net	(38,625,000)	50,281,000
Net before taxes	64,869,000	64,869,000
Income taxes	487,000	487,000
Net income	(78,378,000)	64,382,000
Balance for common	(78,378,000)	64,382,000
Earnings common share		
Primary	\$(0.70)	\$0.62
Fully Diluted	\$(0.70)	\$0.62
Common Shares:		
Full Diluted	111,225,000	104,301,000
Year-end	114,810,671	76,658,829

Consolidated Balance Sheet Items, as of (\$):

	2019
Assets:	
Cash & equivalents	1,491,000
Current assets	1,491,000
Net property & equip.	1,312,333,000
Total assets	1,420,138,000
Liabilities:	
Current liabilities	1,012,634,000
Long-term debt	416,328,000
Stockholders' equity	(262,881,000)
Net current assets	(908,133,000)

LEXARIA BIOSCIENCE CORP

Incentive Stock Options On May 22, 2019, Co. announced that it issued Incentive Stock Options, pursuant to Co.'s registered equity compensation plan, as approved by its directors on May 1, 2019 (the "Options"). The Options were being issued to an independent consultant entitling the holder to purchase of up 48,000 common shares ("Shares") at a price of US\$0.96 per Share. The Options are vested over a two-year period with 16,000 Options being exercisable immediately, 16,000 Options being exercisable on Feb. 24, 2020 and 16,000 Options being exercisable on Feb. 24, 2021. The Options would be subject to a four month hold period from the date of issue pursuant to Canadian Securities Exchange policy.

LEXARIA BIOSCIENCE CORP

Share Purchase Warrants On May 22, 2019, Co. announced that it issued Share Purchase Warrants ("Warrants") to Oak Hill Financial Services Ltd. ("Oak Hill"), a consultant engaged by Co. to perform investor relations services, which Warrants entitle Oak Hill to purchase up to 100,000 Shares at a price of US\$0.96 per Share. The Warrants were exercisable for a period of two (2) years, however only Warrants to purchase up to 50,000 Shares may be exercised until Nov. 22, 2019. The Warrants would be subject to a four month hold period from the date of issue pursuant to Canadian Securities Exchange policy.

LIGHTWAVE LOGIC INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Cost & expenses	1,720,483	1,476,267
Operating income	(1,720,483)	(1,476,267)
Other income (expense), net	(298,357)	(37,194)
Net income	(2,018,778)	(1,513,399)
Earnings common share		
Primary	\$(0.03)	\$(0.02)
Fully Diluted	\$(0.03)	\$(0.02)
Common Shares:		
Full Diluted	80,434,957	74,543,897
Year-end	81,572,469	75,000,557
Consolidated Balance Sheet Items, as of (\$):		
Assets:		2019
Cash & equivalents	2,285,631	2,285,631
Current assets	2,581,055	2,581,055
Net property & equip.	1,725,485	1,725,485
Total assets	6,121,273	6,121,273
Liabilities:		
Current liabilities	329,039	329,039
Stockholders' equity	4,812,435	4,812,435
Net current assets	2,252,016	2,252,016

LINCOLN EDUCATIONAL SERVICES CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	63,263	61,889
Cost & expenses	68,127	68,151
Operating income	(4,864)	(6,262)
Interest income	4	10
Interest expense	557	572
Net before taxes	(5,417)	(6,824)
Income taxes	50	50
Net income	(5,467)	(6,874)
Earnings common share		
Primary	\$(0.22)	\$(0.28)
Fully Diluted	\$(0.22)	\$(0.28)
Common Shares:		
Full Diluted	24,534	24,138
Year-end	25,115	30,570

Consolidated Balance Sheet Items, as of (\$000):

	2019
Assets:	
Cash & equivalents	5,683
Inventories	1,692
Current assets	37,736
Net property & equip.	47,776
Total assets	155,989
Liabilities:	
Current liabilities	59,751
Long-term debt	20,958
Stockholders' equity	34,587
Net current assets	(22,015)

LOGICBIO THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	8,118	2,373
Operating income	(8,118)	(2,373)
Other income (expense), net	3	3
Net before taxes	(7,675)	(2,302)
Income taxes	22	2
Net income	(7,697)	(2,304)
Balance for common	(7,697)	(4,907)
Earnings common share		
Primary	\$(0.34)	\$(2.75)
Fully Diluted	\$(0.34)	\$(2.75)
Common Shares:		
Full Diluted	22,313	1,787
Year-end	22,349	1,780

Consolidated Balance Sheet Items, as of (\$000):

	2019
Assets:	
Cash & equivalents	27,870
Current assets	74,299
Net property & equip.	880
Total assets	76,641
Liabilities:	
Current liabilities	3,767
Stockholders' equity	72,816
Net current assets	70,532

LONESTAR RESOURCES US INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	40,741,000	36,692,000
Cost & expenses	47,272,000	11,727,000
Operating income	(24,501,000)	9,540,000
Interest expense	10,656,000	9,258,000
Other income (expense), net	(36,340,000)	(19,927,000)
Net before taxes	(71,497,000)	(19,645,000)
Income taxes	(12,933,000)	(3,109,000)
Net income	(58,564,000)	(16,536,000)
Balance for common	(60,629,000)	(18,425,000)
Earnings common share		
Primary	\$(2.45)	\$(0.75)
Fully Diluted	\$(2.45)	\$(0.75)
Common Shares:		
Full Diluted	24,698,372	24,559,132
Year-end	24,773,643	24,634,313

Consolidated Balance Sheet Items, as of (\$):

	2019
Assets:	
Cash & equivalents	3,767,000
Current assets	29,744,000
Net property & equip.	662,810,000
Total assets	696,987,000
Liabilities:	
Current liabilities	70,089,000
Long-term debt	448,149,000
Stockholders' equity	164,610,000
Net current assets	(40,345,000)

LOOP INDUSTRIES INC**Annual Report****Consolidated Income Statement, Years Ended Feb. 28 (\$):**

	2019	2018	2017
		(revised)	(revised)
Research & development expenses	3,448,547	6,694,778	1,454,440
General & administrative expenses	8,811,237	6,860,623	2,280,281
Legal settlement expenses	4,041,627
Depreciation & amortization	502,997	367,176	397,445
Impairment of intangible assets	298,694
Foreign exchange loss (gain)	33,773	(109,676)	18,165
Total operating expenses	17,536,411	14,037,378	4,114,001
Interest & other finance costs	(467,082)	(5,125)	...
Net income (loss)	(17,536,411)	(14,037,378)	(4,114,001)
Weighted average shares outstanding			
- basic	33,795,600	32,642,741	31,102,004
Weighted average shares outstanding-diluted	33,795,600	32,642,741	31,102,004
Year end shares outstanding	33,805,706	33,751,088	31,451,973
Net earnings (loss) per share - basic	\$(0.52)	\$(0.43)	\$(0.13)
Net earnings (loss) per share - diluted	\$(0.52)	\$(0.43)	\$(0.13)
Total number of employees	34	28	...
Number of common stockholders	78	109	...

¹ Restated to reflect the adoption of FASB ASU 2016-09, (Topic 718); ² As Is; ³ As of May 2, 2019; ⁴ As of May 4, 2018; ⁵ Approximately

Consolidated Balance Sheet, Years Ended Feb. 28 (\$):

	2019	2018
		(revised)
Cash	5,833,390	8,149,713
Valued added tax & tax credits receivable	599,000	364,634
Prepaid expenses	226,521	511,573
Total current assets	6,658,911	9,025,920
Buildings	1,882,665	1,935,423
Land	232,699	239,239
Building improvements	383,985	377,253

Machinery & equipment	3,834,338	2,189,195
Office equipment & furniture	117,088	101,756
Property & equipment, gross	6,450,775	4,842,866
Less: accumulated amortization	1,079,512	805,963
Property & equipment, net	5,371,263	4,036,903
Intangible assets, net	127,672	332,740
Total assets	12,157,846	13,395,563
Accounts payable & accrued liabilities	2,670,233	1,983,072
Convertible notes	5,636,172	...
Warrants	219,531	...
Current portion of long-term debt	53,155	54,649
Total current liabilities	8,579,091	2,037,721
Instalment loan	1,005,518	...
Less current portion	53,155	...
Long-term debt	952,363	1,033,777
Total liabilities	9,531,454	3,071,498
Common stock	3,381	3,376
Additional paid in capital	38,966,208	30,964,970
Additional paid-in capital - warrants	757,704	...
Additional paid-in capital - beneficial conversion option	1,200,915	...
Common stock issuable	800,000	800,000
Retained earnings (deficit accumulated)	(38,811,592)	(21,275,181)
Accumulated other comprehensive gain (loss)	(290,224)	(169,100)
Total stockholders' equity (deficit)	2,626,392	10,324,065

Recent Dividends:**1. Loop Industries Inc series A preferred.**

No dividends paid.

2. Loop Industries Inc common.

No dividends paid.

Annual Dividends:**1. Loop Industries Inc series A preferred.**

No dividends paid.

2. Loop Industries Inc common.

No dividends paid.

LOOP INDUSTRIES INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, PricewaterhouseCoopers LLP, as it appeared in the 2019 10K report: "In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of February 28, 2019, and the results of its operations and its cash flows for the year ended in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of February 28, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has yet to earn any revenues, suffers recurring losses from operations since its inception, and incurs net cash outflows from operating activities, which all raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

LOVESAC CO

Secondary Offering On May 20, 2019, Co. announced the commencement of an underwritten public offering of 2,500,000 shares of its common stock, which would include 750,000 shares to be offered by Co. and 1,750,000 shares to be offered by certain selling stockholders of Co. One of the selling stockholders would also grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of Co.'s common stock. Co. plans to use the net proceeds of this offering for increased sales and marketing expenses, product development, and working capital and other general corporate purposes. Co. would not receive any of the proceeds from the sale of the shares being offered by the

selling stockholders but would bear the costs associated with the sale of such shares, other than underwriting discounts and commissions.

LUMINEX CORP

Dividend Announcement On May 21, 2019, Co.'s Board of Directors has declared a cash dividend for the second quarter of 2019 of \$0.06 per share of common stock, payable on July 11, 2019 to stockholders of record as of the close of business June 20, 2019.

LYFT INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	776,027,000	397,188,000
Cost & expenses	1,932,917,000	642,567,000
Operating income	(L156,890,000)	245,379,000
Interest income	19,654,000	11,501,000
Other income (expense), net	146,000	(55,000)
Net before taxes	(1,137,090,000)	233,933,000
Income taxes	1,383,000	406,000
Net income	(1,138,473,000)	234,339,000

Earnings common share

Primary	\$(48.53)	\$(11.69)
Fully Diluted	\$(48.53)	\$(11.69)

Common Shares:

Full Diluted	23,459,000	20,039,000
Year-end	35,831,684	20,251,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	329,515,000
Current assets	1,380,412,000
Net property & equip.	120,473,000
Total assets	3,240,907,000
Liabilities:	
Current liabilities	1,752,063,000
Stockholders' equity	(3,931,618,000)
Net current assets	(371,651,000)

MATTRESS FIRM HOLDING CORP

Official Changes On May 24, 2019, Co.'s Board of Directors has appointed John Eck as President and Chief Executive Officer, effective May 28, 2019.

MERCURY SYSTEMS INC

Secondary Offering On May 22, 2019, Co. announced that it priced its previously announced underwritten public offering at \$69.00 per share and increased the size of the offering from 5,000,000 to 6,000,000 shares of its common stock. The offering includes a 30-day option for the underwriters to purchase up to an additional 900,000 shares of common stock at the same per share price. The offering was expected to close on May 28, 2019, subject to customary conditions.

MERITAGE HOSPITALITY GROUP INC**Earnings, 3 mos. to (Consol. - \$):**

	03/31/19	04/01/18
Cost & expenses	101,113,475	92,750,970
Deprec., depl. & amort.	3,240,608	2,760,254
Operating income	5,401,935	4,193,959
Interest expense	3,324,048	2,496,641
Other income (expense), net	3,417,155	(321,732)
Net before taxes	5,495,042	1,375,586
Income taxes	1,424,937	(37,330)
Net income	4,070,105	1,412,916

Earnings common share

Common Shares:	
Year-end	6,292,460

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	22,263,649
Inventories	3,051,976
Current assets	28,642,550
Net property & equip.	114,502,805
Total assets	620,107,254
Liabilities:	
Current liabilities	78,796,049
Long-term debt	156,596,660
Stockholders' equity	74,254,855
Net current assets	(50,153,499)

MERSANA THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	41,035	3,064
Cost & expenses	19,586	15,827
Interest income	452	360
Net income	21,901	(12,403)

Earnings common share

Primary	\$0.72	\$(0.54)
Fully Diluted	\$0.70	\$(0.54)

Common Shares:

Full Diluted	31,462	22,817
Year-end	47,684	22,870

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	137,279
Current assets	141,073
Net property & equip.	2,868
Total assets	149,388
Liabilities:	
Current liabilities	22,595
Stockholders' equity	124,072
Net current assets	118,478

MODERNA INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	16,025	29,039
Cost & expenses	157,858	106,441
Operating income	(141,833)	(77,402)
Interest income	10,972	5,209
Other income (expense), net	(1,820)	(183)
Net before taxes	(132,681)	...
Income taxes	(24)	...
Net income	(132,657)	(72,376)

Balance for common

(132,657) (75,857)

Earnings common share

Primary	\$(0.40)	\$(1.16)
Fully Diluted	\$(0.40)	\$(1.16)

Common Shares:

Full Diluted	328,810	65,431
Year-end	328,853	65,544

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	502,934
Current assets	1,140,827
Net property & equip.	213,460
Total assets	1,806,207
Liabilities:	
Current liabilities	159,159
Stockholders' equity	1,446,033
Net current assets	981,668

MORNINGSTAR INC

Dividend Announcement On May 17, 2019, Co.'s Board of Directors declared a quarterly dividend of \$0.28 per share, payable on July 31, 2019 to shareholders of record as of July 5, 2019.

MUSTANG BIO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	9,754	6,427
Operating income	(9,754)	(6,427)
Interest income	152	146
Net income	(9,613)	(6,281)

Earnings common share

Primary	\$(0.34)	\$(0.24)
Fully Diluted	\$(0.34)	\$(0.24)

Common Shares:

Full Diluted	27,946	26,387
Year-end	28,561	27,102

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	35,600
Current assets	41,612
Net property & equip.	6,864
Total assets	50,485
Liabilities:	
Current liabilities	7,373
Long-term debt	12,725
Stockholders' equity	28,478
Net current assets	34,239

NASDAQ INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	1,039,000	1,151,000
Cost & expenses	716,000	825,000
Deprec., depl. & amort.	48,000	53,000
Operating income	275,000	273,000

Other income (expense), net	45,000	2,000
Gains or losses	27,000	
Net before taxes	313,000	239,000
Income taxes	66,000	62,000
Net income	247,000	177,000
Balance for common	247,000	177,000

Earnings common share		
Primary	\$1.49	\$1.06
Fully Diluted	\$1.48	\$1.05

Common Shares:		
Full Diluted	167,027	168,993
Year-end	165,701	166,947

Consolidated Balance Sheet Items, as of (\$000):		
Assets:	2019	2018
Cash & equivalents	472,000	
Current assets	4,736,000	
Net property & equip.	370,000	
Total assets	14,503,000	
Liabilities:		
Current liabilities	5,641,000	
Long-term debt	2,328,000	
Stockholders' equity	5,494,000	
Net current assets	(905,000)	

NATURAL ALTERNATIVES INTERNATIONAL, INC.

Earnings, 9 mos. to Mar 31(Consol. - \$):

	2019	2018
Net Sales	108,030,000	93,224,000
Cost & expenses	101,264,000	86,537,000
Operating income	6,766,000	6,687,000
Interest income	1,495,000	823,000
Interest expense	23,000	6,000
Other income (expense), net	(1,000)	(18,000)
Foreign currency	191,000	(413,000)
Net before taxes	8,428,000	7,073,000
Income taxes	1,694,000	4,906,000
Net income	6,734,000	2,167,000
Earnings common share		
Primary	\$0.99	\$0.33
Fully Diluted	\$0.95	\$0.32
Common Shares:		
Full Diluted	7,119,589	6,860,870
Year-end	7,259,056	7,568,817

NEON THERAPEUTICS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Cost & expenses	21,580	16,757
Operating income	(21,580)	(16,757)
Interest income	556	247
Other income (expense), net		(10)
Net income	(21,024)	(16,520)
Balance for common	(21,024)	(19,706)
Earnings common share		
Primary	\$(0.76)	\$(9.47)
Fully Diluted	\$(0.76)	\$(9.47)
Common Shares:		
Full Diluted	27,651	2,081
Year-end	28,331	3,303

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	2018
Cash & equivalents	49,264	
Current assets	83,613	
Net property & equip.	8,488	
Total assets	101,040	
Liabilities:		
Current liabilities	11,459	
Stockholders' equity	82,071	
Net current assets	72,154	

NET 1 UEPS TECHNOLOGIES INC

Earnings, 9 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	309,518	463,695
Cost & expenses	342,852	387,788
Operating income	(63,862)	48,877
Interest income	586	14,903
Interest expense	9,030	6,872
Gains or losses	(47,239)	37,843
Equity earnings	338	(7,389)
Net before taxes	(119,545)	94,751
Income taxes	1,702	39,757
Net income	(121,585)	62,383
Earnings common share		

Primary	\$(2.18)	\$1.08
Fully Diluted	\$(2.18)	\$1.08
Common Shares:		
Full Diluted	55,989	55,928
Year-end	56,816	

NETWORK CN INC.

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Cost & expenses	80,153	102,631
Operating income	(80,153)	(102,631)
Interest income	3	
Interest expense	143,575	140,446
Net income	(223,725)	(243,077)
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	8,733,896	8,091,195
Year-end	8,769,013	8,268,795

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	2018
Cash & equivalents	24,460	
Current assets	124,460	
Net property & equip.	1,096	
Total assets	125,556	
Liabilities:		
Current liabilities	12,108,093	
Stockholders' equity	(11,982,537)	
Net current assets	(11,983,633)	

NEVADA CANYON GOLD CORP

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Cost & expenses	105,068	9,927
Operating income	1,037,497	(372,949)
Interest income	468	
Other income (expense), net	890,801	(363,022)
Gains or losses	247,524	
Foreign currency	3,772	
Net before taxes		(372,949)
Net income	1,037,497	(350,971)
Earnings common share		
Primary	\$0.02	\$(0.01)
Fully Diluted	\$0.02	\$(0.01)
Common Shares:		
Full Diluted	44,550,000	44,550,000
Year-end	44,550,000	44,550,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	2018
Cash & equivalents	440,703	
Current assets	442,170	
Total assets	2,033,286	
Liabilities:		
Current liabilities	1,189,705	
Stockholders' equity	843,581	
Net current assets	(747,535)	

NEW CENTURY RESOURCES CORP

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Cost & expenses	4,845	5,376
Operating income	(4,845)	(5,376)
Interest expense	398	398
Net income	(5,243)	(5,774)
Earnings common share		
Common Shares:		
Full Diluted	12,481,724	12,481,724
Year-end	12,481,724	12,481,724

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	2018
Current liabilities	192,389	
Stockholders' equity	(192,389)	
Net current assets	(192,389)	

NEWMARK GROUP INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	447,656	430,460
Cost & expenses	371,842	360,825
Deprec., depl. & amort.	28,304	22,513
Operating income	30,093	39,420

Other income (expense), net	(9,718)	5,707
Net before taxes	30,093	39,420
Income taxes	6,687	6,933
Net income	23,406	32,487
Balance for common	16,904	19,997

Earnings common share		
Primary	\$0.08	\$0.13
Fully Diluted	\$0.08	\$0.12
Common Shares:		
Full Diluted	269,057	246,834
Year-end	178,708	154,762

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	2018
Cash & equivalents	72,527	
Current assets	1,552,067	
Net property & equip.	81,845	
Total assets	3,453,198	
Liabilities:		
Current liabilities	1,523,759	
Long-term debt	538,626	
Stockholders' equity	564,084	
Net current assets	28,308	

NII HOLDINGS INC.

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	146,815	181,241
Cost & expenses	137,578	186,809
Operating income	881	(13,293)
Interest income	3,769	5,386
Interest expense	29,322	26,606
Other income (expense), net	28,129	(6,330)
Foreign currency	(1,618)	(1,188)
Income contin. oper.	1,839	(42,031)
Net income	(858)	(42,152)

Earnings common share		
Primary	\$(0.01)	\$(0.42)
Fully Diluted	\$(0.01)	\$(0.42)

Common Shares:		
Full Diluted	103,235	100,385
Year-end	101,581	100,385

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	2018
Cash & equivalents	200,712	
Inventories	1,461	
Current assets	475,555	
Net property & equip.	147,377	
Total assets	1,382,268	
Liabilities:		
Current liabilities	393,895	
Long-term debt	622,764	
Stockholders' equity	(109,971)	
Net current assets	81,660	

NLIGHT INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	41,861	42,467
Cost & expenses	42,913	38,259
Operating income	(1,052)	4,208
Other income (expense), net	820	76
Net before taxes	518	4,065
Income taxes	1,753	1,149
Net income	(1,235)	2,916
Balance for common	(1,235)	

Earnings common share		
Primary	\$(0.03)	
Fully Diluted	\$(0.03)	

Common Shares:		
Full Diluted	36,694	3,031
Year-end	36,906	3,056

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	2018
Cash & equivalents	142,366	
Inventories	40,846	
Current assets	219,194	
Net property & equip.	22,135	
Total assets	251,531	
Liabilities:		
Current liabilities	24,068	
Long-term debt	19	
Stockholders' equity	218,663	
Net current assets	195,126	

NOVAN INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2019	2018
Total Revenues	1,100	658
Cost & expenses	7,821	9,215
Operating income	(6,721)	(8,557)
Interest income	28	44
Interest expense		262
Other income (expense), net	(332)	3,558
Net income	(7,025)	(5,217)
Earnings common share		
Primary	\$(0.27)	\$(0.21)
Fully Diluted	\$(0.27)	\$(0.21)
Common Shares:		
Full Diluted	26,066	25,027
Year-end	26,070	26,039

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	2018
Cash & equivalents	6,077	7,188
Current assets	7,188	11,657
Net property & equip.	11,657	21,793
Total assets	21,793	
Liabilities:		
Current liabilities	10,723	(2,363)
Stockholders' equity	(2,363)	(3,535)
Net current assets	(3,535)	

OMNITEK ENGINEERING CORP**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2019	2018
Cost & expenses	451,975	451,824
Deprec., depl. & amort.	160	3,981
Operating income	(100,787)	(96,275)
Interest expense	5,439	2,765
Other income (expense), net		950
Net income	(106,226)	(98,090)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	20,420,402	20,281,082
Year-end	20,420,402	20,281,082

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	2018
Cash & equivalents	33,533	1,310,966
Inventories	1,310,966	1,408,123
Current assets	1,408,123	2,216
Net property & equip.	2,216	1,440,764
Total assets	1,440,764	
Liabilities:		
Current liabilities	1,426,324	14,440
Stockholders' equity	14,440	(18,201)
Net current assets	(18,201)	

ORIGIN BANCORP INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2019	2018
Cost & expenses	48,854	35,053
Operating income	17,244	16,191
Net before taxes	17,244	16,191
Income taxes	3,089	2,784
Net income	14,155	13,407
Balance for common	14,155	11,739
Earnings common share		
Primary	\$0.60	\$0.60
Fully Diluted	\$0.60	\$0.60
Common Shares:		
Full Diluted	23,776	19,675
Year-end	23,746	19,525

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	2018
Cash & equivalents	111,240	111,240
Current assets	111,240	78,684
Net property & equip.	78,684	4,872,201
Total assets	4,872,201	
Liabilities:		
Current liabilities	3,898,248	344,704
Long-term debt	344,704	568,122
Stockholders' equity	568,122	(3,787,008)
Net current assets	(3,787,008)	

ORTHOPEDIATRICS CORP**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2019	2018
Total Revenues	14,656	12,094
Cost & expenses	17,373	16,489
Operating income	(2,717)	(4,395)
Interest expense	303	552
Other income (expense), net		(53)
Net income	(3,020)	(5,000)
Balance for common	(3,020)	(5,000)
Earnings common share		
Primary	\$(0.21)	\$(0.41)
Fully Diluted	\$(0.21)	\$(0.41)
Common Shares:		
Full Diluted	14,367	12,074
Year-end	14,682	12,771

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	2018
Cash & equivalents	52,774	28,081
Inventories	28,081	93,111
Current assets	93,111	16,789
Net property & equip.	16,789	112,006
Total assets	112,006	
Liabilities:		
Current liabilities	10,823	21,134
Long-term debt	21,134	80,049
Stockholders' equity	80,049	82,288
Net current assets	82,288	

P & F INDUSTRIES, INC.**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2019	2018
Total Revenues	14,322,000	15,742,000
Cost & expenses	14,310,000	15,588,000
Operating income	12,000	154,000
Interest expense	63,000	37,000
Other income (expense), net		(29,000)
Net before taxes	(51,000)	88,000
Income taxes	(25,000)	23,000
Net income	(26,000)	65,000
Earnings common share		
Primary	\$(0.01)	\$0.02
Fully Diluted	\$(0.01)	\$0.02
Common Shares:		
Full Diluted	3,381,000	3,745,000
Year-end	3,176,000	3,588,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	2018
Cash & equivalents	898,000	20,607,000
Inventories	20,607,000	31,868,000
Current assets	31,868,000	9,854,000
Net property & equip.	9,854,000	55,665,000
Total assets	55,665,000	
Liabilities:		
Current liabilities	12,618,000	353,000
Long-term debt	353,000	42,235,000
Stockholders' equity	42,235,000	19,250,000
Net current assets	19,250,000	

PAPA MURPHY'S HOLDINGS INC

Merger Completed On May 23, 2019, MTY Food Group Inc. ("MTY") wholly-owned subsidiary, MTY Franchising USA, Inc. ("Parent"), through its wholly-owned subsidiary, MTY Columbia Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each outstanding shares of common stock, par value \$0.01 per share, (other than shares held in the treasury of Co. and any shares owned by Merger Sub or irrevocably accepted for purchase by Merger Sub in the Offer and shares held by any Co.'s stockholder who has validly exercised its appraisal rights under the DGCL) was canceled and converted automatically into the right to receive an amount in cash equal of \$6.45 per Share (the "Offer Price"), net to the seller in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). In addition, at the Effective Time, (1) each outstanding Co. stock option, whether or not then exercisable or vested, was canceled and converted into the right to receive an amount in cash, without interest and subject to any required withholding taxes, equal to the excess, if any, of the Merger Consideration over the per share exercise price applicable to such Co. stock option, multiplied by the total number of shares subject to such Co. stock option, (2) each outstanding award of time-based restricted stock units and each earned award of performance-based restricted stock units vested as of immediately before the Effective Time and was canceled

and converted into the right to receive an amount in cash, without interest and subject to any required withholding taxes, equal to the Merger Consideration, multiplied by the number of shares of Common Stock subject to such award, and (3) each outstanding unearned award of performance-based restricted stock units vested at the target level for such award as of immediately before the Effective Time and was canceled and converted into the right to receive an amount in cash, without interest and subject to any required withholding taxes, equal to the Merger Consideration, multiplied by the number of shares of Common Stock subject to such award. The aggregate consideration paid in the Offer and the Merger was approximately \$190,000,000, excluding related transaction fees and expenses.

PATRIOT TRANSPORTATION HOLDING INC (NEW)**Earnings, 6 mos. to Mar 31**(Consol. – \$000):

	2019	2018
Total Revenues	55,062	55,880
Cost & expenses	49,716	50,875
Operating income	1,400	452
Interest income	214	33
Interest expense	17	19
Net before taxes	1,597	466
Income taxes	424	(2,938)
Net income	1,173	3,404
Earnings common share		
Primary	\$0.35	\$1.03
Fully Diluted	\$0.35	\$1.03
Common Shares:		
Full Diluted	3,336	3,311
Year-end	3,347	3,323

PC-TEL INC**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2019	2018
Total Revenues	20,590,000	21,731,000
Cost & expenses	20,986,000	22,828,000
Operating income	(469,000)	(1,221,000)
Other income (expense), net	(4,000)	1,000
Foreign currency	(57,000)	(69,000)
Net before taxes	(307,000)	(1,170,000)
Income taxes	10,000	(312,000)
Net income	(317,000)	(858,000)
Earnings common share		
Primary	\$(0.02)	\$(0.05)
Fully Diluted	\$(0.02)	\$(0.05)
Common Shares:		
Full Diluted	17,617,000	17,056,000
Year-end	18,417,701	18,258,643

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	2018
Cash & equivalents	4,455,000	12,919,000
Inventories	12,919,000	65,928,000
Current assets	65,928,000	11,740,000
Net property & equip.	11,740,000	83,320,000
Total assets	83,320,000	
Liabilities:		
Current liabilities	13,549,000	117,000
Long-term debt	117,000	68,903,000
Stockholders' equity	68,903,000	52,379,000
Net current assets	52,379,000	

PENN NATIONAL GAMING INC

Acquisition Completed On May 23, 2019, Co.'s wholly-owned subsidiary, Penn Tenant III, LLC, acquired the operations of Greektown Casino-Hotel in Detroit, Michigan ("Greektown") through the acquisition of the limited liability company interests in Greektown Holdings, L.L.C., from Greektown Motherhood LLC for an aggregate purchase price of approximately \$300,000,000.

PERCEPTRON, INC.**Earnings, 9 mos. to Mar 31**(Consol. – \$000):

	2019	2018
Net Sales	58,627	61,099
Cost & expenses	56,811	58,006
Operating income	1,816	3,093
Other income (expense), net	33	49
Foreign currency	(178)	(16)
Net before taxes	1,599	2,989
Income taxes	225	45
Net income	1,374	2,944
Earnings common share		
Primary	\$0.14	\$0.31
Fully Diluted	\$0.14	\$0.31
Common Shares:		

Full Diluted	9,711	9,542	Stockholders' equity	44,082	Liabilities:			
Year-end	9,644	9,552	Net current assets	50,278	Current liabilities	16,628		
					Long-term debt	7,572		
					Stockholders' equity	34,215		
					Net current assets	34,891		
PERFORMANT FINANCIAL CORP			PIONEER POWER SOLUTIONS INC			RCI HOSPITALITY HOLDINGS INC		
Earnings, 3 mos. to Mar 31(Consol. - \$000):			Earnings, 3 mos. to Mar 31(Consol. - \$):			Dividend Announcement On May 20, 2019, Co. declared a regular quarterly cash dividend of \$0.03 per common share for the Fiscal 2019 third quarter ending June 30, 2019 as part of its \$0.12 per share annual cash dividend, payable on June 25, 2019, to holders of record June 10, 2019, with an ex-dividend date of June 7, 2019.		
	2019	2018		2019	2018	RCM TECHNOLOGIES, INC.		
Total Revenues	34,876	57,021	Total Revenues	24,699,000	27,177,000	Earnings, 3 mos. to (Consol. - \$):		
Cost & expenses	42,069	44,801	Cost & expenses	24,107,000	26,896,000	03/30/19	03/31/18	
Operating income	(7,193)	12,220	Operating income	592,000	281,000	Total Revenues	51,595,000 50,812,000	
Interest income	11	6	Other income (expense), net	3,295,000	(234,000)	Cost & expenses	49,544,000 48,678,000	
Interest expense	1,136	1,270	Gains or losses	4,207,000		Operating income	1,654,000 1,720,000	
Net before taxes	(8,318)	10,956	Net before taxes	7,595,000	(602,000)	Other income (expense), net	(48,000)	
Income taxes	171	2,501	Income taxes	1,948,000	(28,000)	Foreign currency	11,000 (41,000)	
Net income	(8,489)	8,455	Net income	5,647,000	(574,000)	Net before taxes	1,189,000 1,413,000	
Earnings common share			Earnings common share			Income taxes	(274,000) 362,000	
Primary	\$(0.16)	\$0.16	Primary	\$0.65	\$(0.07)	Net income	1,463,000 1,051,000	
Fully Diluted	\$(0.16)	\$0.16	Fully Diluted	\$0.65	\$(0.07)	Earnings common share		
Common Shares:			Common Shares:			Primary	\$0.11 \$0.09	
Full Diluted	53,059	53,455	Full Diluted	8,730,000	8,726,000	Fully Diluted	\$0.11 \$0.09	
Year-end	53,146	51,495	Year-end	8,726,045		Common Shares:		
						Full Diluted	12,900,834 12,257,507	
						Year-end	12,871,772 12,239,758	
Consolidated Balance Sheet Items, as of (\$000):			Consolidated Balance Sheet Items, as of (\$):			Consolidated Balance Sheet Items, as of (\$):		
Assets:		2019	Assets:		2019	Assets:	2019	
Cash & equivalents		4,364	Cash & equivalents		175,000	Cash & equivalents	1,693,000	
Current assets		27,706	Inventories		27,694,000	Current assets	64,626,000	
Net property & equip.		21,488	Current assets		56,008,000	Net property & equip.	3,272,000	
Total assets		142,600	Net property & equip.		5,168,000	Total assets	92,812,000	
Liabilities:			Total assets		81,878,000	Liabilities:		
Current liabilities		20,681	Liabilities:			Current liabilities	21,255,000	
Long-term debt		40,755	Current liabilities		54,601,000	Long-term debt	34,429,000	
Stockholders' equity		69,114	Long-term debt		2,324,000	Stockholders' equity	29,079,000	
Net current assets		7,025	Stockholders' equity		17,381,000	Net current assets	43,371,000	
			Net current assets		1,407,000			
PETROSHARE CORP			Q2EARTH INC			REDFIN CORP		
Earnings, 3 mos. to Mar 31(Consol. - \$):			Earnings, 3 mos. to Mar 31(Consol. - \$):			Earnings, 3 mos. to Mar 31(Consol. - \$000):		
	2019	2018		2019	2018		2019	2018
Total Revenues	4,971,530	2,068,932	Cost & expenses	766,772	254,343	Total Revenues	110,141	79,893
Cost & expenses	4,285,244	1,078,673	Operating income	(592,962)	(254,343)	Cost & expenses	177,593	117,067
Operating income	(516,953)	248,305	Other income (expense), net	250,188	446,875	Operating income	(67,452)	(37,174)
Interest expense	5,162,222	1,826,733	Invest. income	(21,588)		Interest income	2,316	577
Other income (expense), net	(1,577)	798	Net income	(505,488)	121,532	Interest expense	2,136	
Gains or losses	76,712	89,887	Balance for common	(514,365)	107,888	Other income (expense), net	92	158
Net income	(5,604,040)	(1,487,743)	Earnings common share			Net income	(67,180)	(36,439)
Earnings common share			Primary	\$(0.01)	\$(0.01)	Earnings common share		
Primary	\$(0.20)	\$(0.05)	Fully Diluted	\$(0.01)	\$(0.01)	Primary	\$(0.74)	\$(0.44)
Fully Diluted	\$(0.20)	\$(0.05)	Common Shares:			Fully Diluted	\$(0.74)	\$(0.44)
Common Shares:			Full Diluted	51,997,460	48,424,918	Common Shares:		
Full Diluted	28,077,470	27,775,505	Year-end	51,997,460	48,384,009	Full Diluted	90,610	82,011
Year-end	28,077,332	27,924,765				Year-end	90,926	82,673
Consolidated Balance Sheet Items, as of (\$):			Consolidated Balance Sheet Items, as of (\$):			Consolidated Balance Sheet Items, as of (\$000):		
Assets:		2019	Assets:		2019	Assets:	2019	2018
Cash & equivalents		2,309,517	Cash & equivalents		265,360	Cash & equivalents	395,618	395,618
Current assets		9,718,762	Current assets		268,747	Inventories	38,306	38,306
Net property & equip.		28,306,857	Net property & equip.		221	Current assets	489,982	489,982
Total assets		38,568,210	Total assets		268,968	Net property & equip.	30,618	30,618
Liabilities:			Liabilities:			Total assets	574,610	574,610
Current liabilities		45,998,181	Current liabilities		1,067,209	Liabilities:		
Stockholders' equity		(9,742,397)	Long-term debt		2,850,000	Current liabilities	103,600	103,600
Net current assets		(36,279,419)	Stockholders' equity		(4,369,721)	Long-term debt	115,094	115,094
			Net current assets		(798,462)	Stockholders' equity	314,349	314,349
						Net current assets	386,382	386,382
PHASEBIO PHARMACEUTICALS INC			QUANTERIX CORP			RESTORATION ROBOTICS INC		
Earnings, 3 mos. to Mar 31(Consol. - \$000):			Earnings, 3 mos. to Mar 31(Consol. - \$000):			Earnings, 3 mos. to Mar 31(Consol. - \$000):		
	2019	2018		2019	2018		2019	2018
Cost & expenses	8,037	2,878	Total Revenues	12,337	7,521	Total Revenues	5,394	5,005
Operating income	(7,384)	(2,878)	Cost & expenses	21,694	14,684	Cost & expenses	12,008	12,045
Interest income	317	36	Operating income	(9,357)	(7,163)	Operating income	(6,614)	(7,040)
Interest expense	226	1,404	Other income (expense), net	(47)	(15)	Interest expense	766	358
Other income (expense), net	(157)	(157)	Net before taxes	(9,383)		Other income (expense), net	(46)	(20)
Net income	(7,293)	(4,403)	Income taxes	22		Net before taxes	(7,426)	(7,418)
Earnings common share			Net income	(9,405)	(7,202)	Income taxes	14	13
Primary	\$(0.30)	\$(5.90)	Earnings common share			Net income	(7,440)	(7,431)
Fully Diluted	\$(0.30)	\$(5.90)	Primary	\$(0.42)	\$(0.33)	Balance for common	(7,440)	(7,431)
Common Shares:			Fully Diluted	\$(0.42)	\$(0.33)	Earnings common share		
Full Diluted	24,498	746	Common Shares:					
Year-end	24,498	776	Full Diluted	22,423	21,789			
			Year-end	22,491	21,823			
Consolidated Balance Sheet Items, as of (\$000):			Consolidated Balance Sheet Items, as of (\$000):			Consolidated Balance Sheet Items, as of (\$000):		
Assets:		2019	Assets:		2019	Assets:	2019	2018
Cash & equivalents		51,894	Cash & equivalents		33,972	Total Revenues	5,394	5,005
Current assets		54,075	Inventories		7,742	Cost & expenses	12,008	12,045
Net property & equip.		380	Current assets		51,519	Operating income	(6,614)	(7,040)
Total assets		56,386	Net property & equip.		8,582	Interest expense	766	358
Liabilities:			Total assets		65,176	Other income (expense), net	(46)	(20)
Current liabilities		3,797				Net before taxes	(7,426)	(7,418)
Long-term debt		6,841				Income taxes	14	13

Primary	\$(0.18)	\$(0.26)
Fully Diluted	\$(0.18)	\$(0.26)
Common Shares:		
Full Diluted	40,753	28,962
Year-end	40,767	29,046

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents	14,957	
Inventories	5,207	
Current assets	28,102	
Net property & equip.	1,471	
Total assets	29,822	
Liabilities:		
Current liabilities	11,986	
Long-term debt	22,655	
Stockholders' equity	(5,474)	
Net current assets	16,116	

RESTORBIO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	11,691	10,200
Operating income	(11,691)	(10,200)
Other income (expense), net	631	341
Net before taxes	(11,060)	
Income taxes	9	
Net income	(11,060)	(9,859)
Earnings common share		
Primary	\$(0.38)	\$(0.46)
Fully Diluted	\$(0.38)	\$(0.46)
Common Shares:		
Full Diluted	29,015	21,523
Year-end	35,255	28,046

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents	7,181	
Current assets	144,678	
Net property & equip.	318	
Total assets	145,080	
Liabilities:		
Current liabilities	4,609	
Stockholders' equity	140,456	
Net current assets	140,069	

RIMI STREET INC (DE)**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	66,260,000	59,805,000
Cost & expenses	53,542,000	34,584,000
Operating income	12,718,000	25,221,000
Interest expense	232,000	13,409,000
Other income (expense), net	43,000	(7,789,000)
Net before taxes	12,529,000	4,023,000
Income taxes	705,000	516,000
Net income	11,824,000	3,507,000
Balance for common	4,740,000	3,507,000
Earnings common share		
Primary	\$0.07	\$0.06
Fully Diluted	\$0.07	\$0.05
Common Shares:		
Full Diluted	69,101,000	68,154,000
Year-end	65,242,000	59,440,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		2019
Cash & equivalents	32,264,000	
Current assets	118,170,000	
Net property & equip.	3,673,000	
Total assets	124,183,000	
Liabilities:		
Current liabilities	228,739,000	
Stockholders' equity	(256,652,000)	
Net current assets	(110,569,000)	

ROCKET PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	18,945	14,405
Operating income	(18,945)	(14,405)
Interest income	601	288
Interest expense	1,604	1,427
Other income (expense), net	497	201
Net income	(19,451)	(15,343)
Earnings common share		

Primary	\$(0.43)	\$(0.42)
Fully Diluted	\$(0.43)	\$(0.42)
Common Shares:		
Full Diluted	45,123	36,137
Year-end	45,114	39,404

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents	124,464	
Current assets	199,619	
Net property & equip.	7,077	
Total assets	242,138	
Liabilities:		
Current liabilities	20,572	
Long-term debt	42,297	
Stockholders' equity	177,077	
Net current assets	179,047	

ROCKY BRANDS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Net Sales	65,929,000	61,387,000
Cost & expenses	61,430,000	57,159,000
Operating income	4,499,000	4,228,000
Other income (expense), net	65,000	(139,000)
Net before taxes	4,564,000	4,089,000
Income taxes	959,000	838,000
Net income	3,605,000	3,251,000
Earnings common share		
Primary	\$0.49	\$0.44
Fully Diluted	\$0.48	\$0.44
Common Shares:		
Full Diluted	7,434,000	7,431,000
Year-end	7,391,660	7,406,801

Consolidated Balance Sheet Items, as of (\$):

Assets:		2019
Cash & equivalents	17,630,000	
Inventories	69,905,000	
Current assets	133,405,000	
Net property & equip.	23,438,000	
Total assets	188,406,000	
Liabilities:		
Current liabilities	25,063,000	
Stockholders' equity	154,756,000	
Net current assets	108,342,000	

ROKU INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	206,662	136,576
Cost & expenses	217,402	143,478
Operating income	(10,740)	(6,902)
Interest expense	98	51
Other income (expense), net	967	448
Net before taxes	(9,871)	(6,505)
Income taxes	(139)	129
Net income	(9,732)	(6,634)
Balance for common	(9,732)	(6,634)
Earnings common share		
Primary	\$(0.09)	\$(0.07)
Fully Diluted	\$(0.09)	\$(0.07)
Common Shares:		
Full Diluted	110,877	99,488
Year-end	113,292	100,968

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents	236,500	
Inventories	33,398	
Current assets	520,368	
Net property & equip.	30,777	
Total assets	628,132	
Liabilities:		
Current liabilities	188,862	
Stockholders' equity	360,934	
Net current assets	331,506	

RUBIUS THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	34,406	14,603
Operating income	(34,406)	(14,603)
Interest expense	583	83
Other income (expense), net	2,408	275
Net income	(32,581)	(14,411)

Earnings common share		
Primary	\$(0.42)	\$(1.72)
Fully Diluted	\$(0.42)	\$(1.72)
Common Shares:		
Full Diluted	77,544	8,355
Year-end	79,854	14,997

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents	192,499	
Current assets	385,834	
Net property & equip.	24,577	
Total assets	441,470	
Liabilities:		
Current liabilities	20,700	
Long-term debt	24,431	
Stockholders' equity	371,636	
Net current assets	365,134	

SAGA COMMUNICATIONS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	27,816	28,009
Cost & expenses	25,851	25,690
Operating income	1,965	2,319
Interest income	163	89
Net before taxes	1,920	2,189
Income taxes	550	660
Net income	1,370	1,529
Balance for common	1,344	1,503
Earnings common share		
Primary	\$0.23	\$0.26
Fully Diluted	\$0.23	\$0.26
Common Shares:		
Full Diluted	5,841	5,842
Year-end	5,956	5,933

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents	39,170	
Current assets	59,673	
Net property & equip.	58,379	
Total assets	245,093	
Liabilities:		
Current liabilities	14,417	
Long-term debt	15,000	
Stockholders' equity	185,326	
Net current assets	45,256	

SAVARA INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	12,782	32,000
Operating income	(12,920)	(32,107)
Other income (expense), net	887	868
Foreign currency	(59)	(61)
Net before taxes		(31,404)
Income taxes		(4,555)
Net income	(12,112)	(26,849)
Earnings common share		
Primary	\$(0.34)	\$(0.86)
Fully Diluted	\$(0.34)	\$(0.86)
Common Shares:		
Full Diluted	36,016	31,319
Year-end	35,830	30,604

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents	25,671	
Current assets	107,518	
Net property & equip.	474	
Total assets	148,263	
Liabilities:		
Current liabilities	8,920	
Long-term debt	24,677	
Stockholders' equity	101,804	
Net current assets	98,598	

SB ONE BANCORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	16,400	14,320
Operating income	7,323	1,523
Net before taxes	7,323	1,523
Income taxes	1,500	215
Net income	5,823	1,308

Earnings common share		
Primary	\$0.62	\$0.17
Fully Diluted	\$0.62	\$0.17
Common Shares:		
Full Diluted	9,460	7,792
Year-end	9,471	7,930

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		23,203
Current assets		29,792
Net property & equip.		19,459
Total assets	1,840,129	
Liabilities:		
Current liabilities	1,576,124	
Long-term debt	64,570	
Stockholders' equity	189,695	
Net current assets	(1,546,332)	

SCHOLAR ROCK HOLDING CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	3,106	
Cost & expenses	14,809	9,016
Operating income	(11,703)	(9,016)
Other income (expense), net		(20)
Net income	(10,755)	(8,892)

Earnings common share

Primary	\$(0.42)	\$(3.18)
Fully Diluted	\$(0.42)	\$(3.18)

Common Shares:

Full Diluted	25,593	2,795
Year-end	26,217	3,971

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		67,004
Current assets		162,028
Net property & equip.		3,644
Total assets		170,982
Liabilities:		
Current liabilities		34,075
Stockholders' equity		97,523
Net current assets		127,953

SHOCKWAVE MEDICAL INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	19,428	11,124
Operating income	(12,159)	(9,802)
Interest expense	245	18
Other income (expense), net	(388)	226
Net before taxes	(12,792)	
Income taxes	7	
Net income	(12,799)	(9,594)

Earnings common share

Primary	\$(1.37)	\$(5.63)
Fully Diluted	\$(1.37)	\$(5.63)

Common Shares:

Full Diluted	9,365	1,705
Year-end	27,871	1,770

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		138,064
Inventories		7,014
Current assets		151,525
Net property & equip.		2,803
Total assets		157,539
Liabilities:		
Current liabilities		14,616
Long-term debt		11,821
Stockholders' equity		129,186
Net current assets		136,909

SI-BONE INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	14,991	12,712
Cost & expenses	23,790	15,629
Operating income	(8,799)	(2,917)
Interest income	744	62
Interest expense	1,230	1,275
Other income (expense), net	(60)	(71)
Net income	(9,345)	(4,201)

Earnings common share

Primary	\$(0.38)	\$(1.17)
Fully Diluted	\$(0.38)	\$(1.17)
Common Shares:		
Full Diluted	24,391	3,594
Year-end	24,498	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		12,561
Inventories		3,516
Current assets		129,397
Net property & equip.		2,336
Total assets		132,054
Liabilities:		
Current liabilities		9,908
Long-term debt		39,028
Stockholders' equity		82,755
Net current assets		119,489

SILK ROAD MEDICAL INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	12,766	5,706
Cost & expenses	19,912	10,353
Operating income	(7,146)	(4,647)
Interest income	52	13
Interest expense	1,352	989
Other income (expense), net	(15,712)	215
Net income	(24,158)	(5,408)

Earnings common share

Primary	\$(20.12)	\$(7.31)
Fully Diluted	\$(20.12)	\$(7.31)

Common Shares:

Full Diluted	1,201	739
Year-end	1,387	850

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		15,509
Inventories		8,056
Current assets		29,052
Net property & equip.		2,846
Total assets		38,668
Liabilities:		
Current liabilities		10,792
Long-term debt		44,597
Stockholders' equity		(158,074)
Net current assets		18,260

SMG INDUSTRIES INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	1,752,704	998,178
Cost & expenses	2,319,339	931,957
Operating income	(566,635)	66,221
Net income	(710,262)	19,743

Earnings common share

Primary	\$(0.06)	\$
Fully Diluted	\$(0.06)	\$

Common Shares:

Full Diluted	12,460,520	9,651,888
Year-end	12,873,736	10,005,190

Consolidated Balance Sheet Items, as of (\$):

Assets:		2019
Cash & equivalents		70,432
Inventories		128,425
Current assets		1,250,024
Net property & equip.		2,009,995
Total assets		4,100,468
Liabilities:		
Current liabilities		3,244,349
Long-term debt		1,223,898
Stockholders' equity		(527,212)
Net current assets		(1,994,325)

SMTC CORP.**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/19	04/01/18
Total Revenues	102,649	37,120
Cost & expenses	98,297	36,779
Operating income	4,352	341
Interest expense	2,870	307
Net before taxes	1,482	34
Income taxes	271	26
Net income	1,211	8

Earnings common share		
Primary	\$0.05	\$
Fully Diluted	\$0.05	\$
Common Shares:		
Full Diluted	24,465	17,524
Year-end	23,354	17,092

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		1,596
Inventories		48,660
Current assets		155,432
Net property & equip.		27,213
Total assets		224,827
Liabilities:		
Current liabilities		122,334
Long-term debt		65,555
Stockholders' equity		33,600
Net current assets		33,098

SOLID BIOSCIENCES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Total Revenues	30,302	15,973
Cost & expenses	(30,302)	(15,973)
Operating income		
Interest income	508	65
Other income (expense), net	212	31
Net income	(29,582)	(15,877)

Earnings common share

Primary	\$(0.85)	\$(0.54)
Fully Diluted	\$(0.85)	\$(0.54)

Common Shares:

Full Diluted	34,776	29,355
Year-end	35,415	35,477

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents		53,994
Current assets		101,787
Net property & equip.		11,995
Total assets		120,234
Liabilities:		
Current liabilities		14,572
Long-term debt		813
Stockholders' equity		99,113
Net current assets		87,215

SONOS INC**Earnings, 6 mos. to (Consol. - \$000):**

	03/30/19	03/31/18
Total Revenues	706,544	655,670
Cost & expenses	660,964	643,111
Operating income	45,580	12,559
Other income (expense), net	(4,708)	3,429
Net before taxes	41,085	13,738
Income taxes	2,242	633
Net income	38,843	13,105
Balance for common	38,843	3,753

Earnings common share

Primary	\$0.38	\$0.06
Fully Diluted	\$0.35	\$0.05

Common Shares:

Full Diluted	111,474	73,366
Year-end	105,693	60,707

SORL AUTO PARTS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Cost & expenses	122,447,748	93,731,913
Operating income	13,772,176	13,994,769
Interest income	1,736,775	1,488,264
Interest expense	3,972,498	3,353,711
Other income (expense), net	1,369,173	(729,815)
Foreign currency	(1,061,005)	(601,286)
Net before taxes	11,844,621	10,798,221
Income taxes	1,868,767	1,605,441
Net income	9,975,854	9,192,780

Earnings common share

Primary	\$0.46	\$0.43
Fully Diluted	\$0.46	\$0.43

Common Shares:

Full Diluted	19,304,921	19,304,921
Year-end	19,304,921	19,304,921

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	8,024,006
Inventories	187,384,139
Current assets	596,739,622
Net property & equip.	107,063,204
Total assets	787,337,300
Liabilities:	
Current liabilities	552,120,582
Long-term debt	5,426,193
Stockholders' equity	189,484,969
Net current assets	44,619,040

SPARTANNASH CO.

Dividend Announcement On May 23, 2019, Co.'s Board of Directors approved a quarterly cash dividend of \$0.19 per common share, payable on June 28, 2019 to shareholders of record as of June 14, 2019.

SPARTANNASH CO.

Earnings, 3 mos. to (Consol. - \$):

	04/20/19	04/21/18
Net Sales	2,542,375,000	3,850,730,000
Cost & expenses	2,520,166,000	3,593,325,000
Operating income	22,209,000	25,748,000
Other income (expense), net	(183,000)	225,000
Net before taxes	10,145,000	17,195,000
Income contin. oper.	7,521,000	12,435,000
Income discont. oper.	(52,000)	(92,000)
Net income	7,469,000	12,343,000
Earnings common share		
Primary	\$0.21	\$0.34
Fully Diluted	\$0.21	\$0.34
Common Shares:		
Full Diluted	35,243,000	35,480,000
Year-end	36,319,000	35,923,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	21,360,000
Inventories	595,741,000
Current assets	1,052,823,000
Net property & equip.	623,132,000
Total assets	2,359,496,000
Liabilities:	
Current liabilities	555,105,000
Stockholders' equity	693,802,000
Net current assets	497,718,000

SPERO THERAPEUTICS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	7,718	1,153
Cost & expenses	13,414	11,969
Operating income	(5,696)	(10,816)
Net income	(5,072)	(10,644)
Earnings common share		
Primary	\$(0.29)	\$(0.74)
Fully Diluted	\$(0.29)	\$(0.74)
Common Shares:		
Full Diluted	17,221	14,369
Year-end	17,335	14,369

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	49,395
Current assets	115,702
Net property & equip.	2,864
Total assets	124,650
Liabilities:	
Current liabilities	6,618
Stockholders' equity	112,974
Net current assets	109,084

STEEL DYNAMICS INC.

Dividend Announcement On May 17, 2019, Co.'s Board of Directors has declared a quarterly cash dividend of \$0.24 per common share, payable to shareholders of record at the close of business on June 30, 2019, and is payable on or about July 12, 2019.

STEREOTAXIS INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	7,009,875	6,971,632
Cost & expenses	9,149,261	8,102,149
Operating income	(2,139,386)	(1,130,517)
Interest expense	(16,566)	24,615
Other income (expense), net	2,590,361	1,435,229
Net income	(2,122,820)	1,435,229

Balance for common	(2,476,330)	471,360
Earnings common share		
Primary	\$(0.04)	\$0.02
Fully Diluted	\$(0.04)	\$0.01
Common Shares:		
Full Diluted	59,196,652	33,122,598
Year-end	59,304,222	58,897,111

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	9,040,816
Inventories	1,309,134
Current assets	16,363,434
Net property & equip.	328,614
Total assets	22,442,593
Liabilities:	
Current liabilities	12,462,676
Stockholders' equity	(627,115)
Net current assets	3,900,758

SUTRO BIOPHARMA INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	8,629	5,793
Cost & expenses	22,895	17,496
Operating income	(14,266)	(11,703)
Interest income	1,176	40
Net income	(14,250)	(12,046)
Earnings common share		
Primary	\$(0.62)	\$(25.75)
Fully Diluted	\$(0.62)	\$(25.75)
Common Shares:		
Full Diluted	22,865	468
Year-end	22,925	472

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	26,616
Current assets	176,535
Net property & equip.	9,926
Total assets	202,458
Liabilities:	
Current liabilities	31,130
Long-term debt	8,500
Stockholders' equity	130,718
Net current assets	145,405

SYMANTEC CORP**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	03/29/19	03/30/18	03/31/17
Net revenues	4,731,000	4,834,000	4,019,000
Cost of revenues	1,050,000	1,032,000	853,000
Gross profit	3,681,000	3,802,000	3,166,000
Sales & marketing expense	1,493,000	1,593,000	1,459,000
Research & development expense	913,000	956,000	823,000
General & administrative expenses	447,000	574,000	564,000
Amortization of intangible assets	207,000	220,000	147,000
Restructuring, transition & other costs	241,000	410,000	273,000
Total operating expenses	3,301,000	3,753,000	3,266,000
Operating income (loss)	380,000	49,000	(100,000)
Interest expense	208,000	256,000	208,000
Gain on divestiture	...	653,000	...
Interest income	42,000	24,000	21,000
Gain (loss) from equity interest	(101,000)	(26,000)	...
Foreign exchange gain (loss)	(18,000)	(28,000)	(2,000)
Other income	13,000	21,000	27,000
Other income (expense), net	(64,000)	(9,000)	46,000
Income (loss) from continuing operations before income taxes	108,000	437,000	(262,000)
Current income tax			

expense (benefit) - federal	73,000	1,011,000	108,000
Current income tax expense (benefit) - state	15,000	40,000	6,000
Current income tax expense (benefit) - international	74,000	107,000	68,000
Total current income tax expense (benefit)	162,000	1,158,000	182,000
Deferred income tax expense (benefit) - federal	(52,000)	(1,664,000)	(177,000)
Deferred income tax expense (benefit) - state	(2,000)	(151,000)	(17,000)
Deferred income tax expense (benefit) - international	(16,000)	(33,000)	(14,000)
Total deferred income tax expense (benefit)	(70,000)	(1,848,000)	(208,000)
Income tax expense (benefit)	92,000	(690,000)	(26,000)
Income (loss) from continuing operations	16,000	1,127,000	(236,000)
Income (loss) from discontinued operations, net of income taxes	15,000	11,000	130,000
Net income (loss)	31,000	1,138,000	(106,000)
Weighted average shares outstanding - basic	632,000	616,000	618,000
Weighted average shares outstanding - diluted	661,000	668,000	618,000
Year end shares outstanding	630,000	624,000	608,019
Income (loss) per share from continuing operations - basic	\$0.03	\$1.83	\$(0.38)
Income (loss) per share from discontinued operations - basic	\$0.02	\$0.02	\$0.21
Net income (loss) per share - basic	\$0.05	\$1.85	\$(0.17)
Income (loss) per share from continuing operations - diluted	\$0.02	\$1.69	\$(0.38)
Income (loss) per share from discontinued operations - diluted	\$0.02	\$0.02	\$0.21
Net income (loss) per share - diluted	\$0.05	\$1.70	\$(0.17)
Total number of employees	11,900	11,800	13,000
Number of common stockholders	1,601	1,665	1,763

□ Reclassified to conform with 2019 presentation; □ As is; □ Approximately

Consolidated Balance Sheet, Years Ended (\$000):

	03/29/19	03/30/18
Cash & cash equivalents	1,791,000	1,774,000
Short-term investments	252,000	388,000
Trade accounts receivable, gross	713,000	...
Less: allowance for doubtful accounts	5,000	...
Accounts receivable, net	708,000	809,000
Prepaid expenses	162,000	177,000
Income tax receivable & prepaid income taxes	61,000	107,000
Value-added tax		

receivable & other tax receivables	69,000	24,000	ExDate	Amt	Declared	Record	Payable	
Short-term deferred commissions	92,000	94,000	02/18/2016	0.15	02/04/2016	02/22/2016	03/16/2016	
Assets held for sale	26,000	26,000	03/04/2016	4.00	02/04/2016	03/08/2016	03/22/2016	
Other current assets	51,000	94,000	06/06/2016	0.07	05/12/2016	06/08/2016	06/22/2016	
Other current assets	435,000	522,000	08/18/2016	0.07	08/04/2016	08/22/2016	09/14/2016	
Total current assets	3,186,000	3,493,000	11/17/2016	0.07	11/03/2016	11/21/2016	12/14/2016	
Land	66,000	66,000	02/15/2017	0.07	02/01/2017	02/20/2017	03/15/2017	
Computer hardware & software	1,159,000	1,081,000	06/05/2017	0.07	05/10/2017	06/07/2017	06/21/2017	
Office furniture & equipment	118,000	110,000	08/17/2017	0.07	08/10/2017	08/21/2017	09/13/2017	
Buildings	364,000	365,000	11/17/2017	0.07	11/01/2017	11/20/2017	12/13/2017	
Leasehold improvements	372,000	339,000	02/21/2018	0.07	01/31/2018	02/22/2018	03/14/2018	
Construction in progress	30,000	29,000	06/07/2018	0.07	05/10/2018	06/08/2018	06/20/2018	
Less accumulated depreciation & amortization	1,319,000	1,212,000	08/17/2018	0.07	08/02/2018	08/20/2018	09/12/2018	
Property & equipment, net	790,000	778,000	02/15/2019	0.07	01/31/2019	02/19/2019	03/13/2019	
Intangible assets, net	2,250,000	2,643,000	Annual Dividends:					
Goodwill	8,450,000	8,319,000	1. Symantec Corp common.					
Equity method investment	184,000	175,000	2016	4.38	2017	0.30	2018	0.30
Cost method investments	32,000	134,000	2019	0.08				

SYNACOR, INC.**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2019	2018
Total Revenues	31,824	32,915
Cost & expenses	31,508	32,857
Deprec., depl. & amort.	2,435	2,435
Operating income	(2,119)	(2,377)
Interest expense	64	97
Other income (expense), net	216	119
Net before taxes	(1,967)	(2,355)
Income taxes	277	20
Net income	(2,244)	(2,375)
Earnings common share		
Primary	\$(0.06)	\$(0.06)
Fully Diluted	\$(0.06)	\$(0.06)
Common Shares:		
Full Diluted	39,039	38,794
Year-end	39,053	38,797

Consolidated Balance Sheet Items, as of (\$000):

	2019	2018
Assets:		
Cash & equivalents	13,494	13,494
Current assets	38,801	38,801
Net property & equip.	17,688	17,688
Total assets	92,397	92,397
Liabilities:		
Current liabilities	34,996	34,996
Long-term debt	824	824
Stockholders' equity	49,174	49,174
Net current assets	3,805	3,805

SYNLOGIC INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2019	2018
Total Revenues	338	354
Cost & expenses	14,035	11,990
Operating income	(13,697)	(11,636)
Interest expense	7	14
Other income (expense), net	1	(1)
Net income	(12,946)	(11,165)
Earnings common share		
Primary	\$(0.51)	\$(0.55)
Fully Diluted	\$(0.51)	\$(0.55)
Common Shares:		
Full Diluted	25,294	20,146
Year-end	25,389	22,172

Consolidated Balance Sheet Items, as of (\$000):

	2019	2018
Assets:		
Cash & equivalents	15,744	15,744
Current assets	113,792	113,792
Net property & equip.	14,348	14,348
Total assets	145,000	145,000
Liabilities:		
Current liabilities	9,867	9,867
Long-term debt	141	141
Stockholders' equity	112,210	112,210
Net current assets	103,925	103,925

SYNOPSIS INC**Earnings, 6 mos. to Apr 30(Consol. – \$000):**

	2019	2018
Total Revenues	80,301	59,107
Cost & expenses	102,986	74,556
Operating income	(22,685)	(15,449)
Other income (expense), net	(214)	18
Net before taxes	(21,343)	(15,457)
Income taxes	97	431
Net income	(21,440)	(15,888)
Balance for common	(21,440)	(16,076)
Earnings common share		
Primary	\$(0.23)	\$(0.68)

	2019	2018
Total Revenues	1,656,643	1,546,262
Cost & expenses	1,372,627	1,291,255
Operating income	262,916	234,732
Other income (expense), net	20,657	8,732
Net before taxes	280,972	239,402
Income taxes	9,248	140,621
Net income	271,724	98,781
Earnings common share		
Primary	\$1.82	\$0.66
Fully Diluted	\$1.77	\$0.64
Common Shares:		
Full Diluted	153,383	153,664
Year-end	142,704	148,961

SYPRIS SOLUTIONS, INC.**Earnings, 3 mos. to (Consol. – \$000):**

	03/31/19	04/01/18
Total Revenues	19,564	19,942
Cost & expenses	21,525	21,568
Operating income	(1,961)	(1,626)
Interest expense	217	213
Other income (expense), net	(51)	84
Net before taxes	(2,229)	(1,755)
Income taxes	76	40
Net income	(2,305)	(1,795)
Balance for common	(2,305)	(1,795)
Earnings common share		
Primary	\$(0.11)	\$(0.09)
Fully Diluted	\$(0.11)	\$(0.09)
Common Shares:		
Full Diluted	20,669	20,394
Year-end	21,354	21,356

Consolidated Balance Sheet Items, as of (\$000):

	2019	2018
Assets:		
Cash & equivalents	5,689	5,689
Inventories	21,209	21,209
Current assets	41,877	41,877
Net property & equip.	14,758	14,758
Total assets	65,676	65,676
Liabilities:		
Current liabilities	27,999	27,999
Long-term debt	9,342	9,342
Stockholders' equity	14,158	14,158
Net current assets	13,878	13,878

TCR2 THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2019	2018
Cost & expenses	10,775	4,113
Operating income	(10,775)	(4,113)
Interest income	872	127
Net income	(9,903)	(3,986)
Balance for common	(59,803)	(14,819)
Earnings common share		
Primary	\$(4.85)	\$(28.90)
Fully Diluted	\$(4.85)	\$(28.90)
Common Shares:		
Full Diluted	12,329	513
Year-end	23,792	599

Consolidated Balance Sheet Items, as of (\$000):

	2019	2018
Assets:		
Cash & equivalents	46,405	46,405
Current assets	165,585	165,585
Net property & equip.	1,936	1,936
Total assets	197,859	197,859
Liabilities:		
Current liabilities	5,357	5,357
Stockholders' equity	192,047	192,047
Net current assets	160,228	160,228

TENABLE HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2019	2018
Total Revenues	80,301	59,107
Cost & expenses	102,986	74,556
Operating income	(22,685)	(15,449)
Other income (expense), net	(214)	18
Net before taxes	(21,343)	(15,457)
Income taxes	97	431
Net income	(21,440)	(15,888)
Balance for common	(21,440)	(16,076)
Earnings common share		
Primary	\$(0.23)	\$(0.68)

□ Reclassified to conform with 2019 presentation

Recent Dividends:

1. Symantec Corp common.

Fully Diluted	\$(0.23)	\$(0.68)
Common Shares:		
Full Diluted	93,738	23,495
Year-end	96,203	24,794
Consolidated Balance Sheet Items, as of (\$000):		
Assets:		2019
Cash & equivalents	167,966	
Current assets	400,429	
Net property & equip.	12,714	
Total assets	466,391	
Liabilities:		
Current liabilities	250,783	
Stockholders' equity	128,209	
Net current assets	149,646	

TEXAS ROADHOUSE INC

Dividend Announcement On May 24, 2019, Co.'s Board of Directors authorized the payment of a cash dividend of \$0.30 per share of common stock, to be distributed on June 28, 2019, to shareholders of record at the close of business on June 12, 2019.

TILRAY INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	23,038	7,808
Cost & expenses	49,049	11,326
Operating income	(27,874)	(3,740)
Interest expense	8,745	416
Other income (expense), net	2,480	121
Foreign currency	(179)	(1,146)
Net before taxes	(34,318)	
Net income	(30,301)	(5,181)
Earnings common share		
Primary	\$(0.32)	\$(0.07)
Fully Diluted	\$(0.32)	\$(0.07)
Common Shares:		
Full Diluted	94,875	75,000
Year-end	96,798	75,000

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	294,205	
Inventories	48,712	
Current assets	399,589	
Net property & equip.	128,963	
Total assets	1,076,596	
Liabilities:		
Current liabilities	170,364	
Long-term debt	431,529	
Stockholders' equity	381,920	
Net current assets	229,225	

TONIX PHARMACEUTICALS HOLDING CORP

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Cost & expenses	6,297,000	6,988,000
Operating income	(6,297,000)	(6,988,000)
Net income	(6,233,000)	(6,935,000)
Earnings common share		
Primary	\$(1.29)	\$(8.80)
Fully Diluted	\$(1.29)	\$(8.80)
Common Shares:		
Full Diluted	4,848,199	785,030
Year-end	6,089,728	801,079

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	16,448,000	
Current assets	19,182,000	
Net property & equip.	41,000	
Total assets	20,022,000	
Liabilities:		
Current liabilities	2,011,000	
Stockholders' equity	17,811,000	
Net current assets	17,171,000	

TRACON PHARMACEUTICALS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Cost & expenses	7,163	11,189
Operating income	(7,163)	(8,189)
Interest expense	46	169
Other income (expense), net	(4)	(6)
Net income	(7,213)	(8,364)
Earnings common share		
Primary	\$(0.24)	\$(0.46)

Fully Diluted	\$(0.24)	\$(0.46)
Common Shares:		
Full Diluted	29,892	18,215
Year-end	29,899	28,442
Consolidated Balance Sheet Items, as of (\$000):		
Assets:	2019	
Cash & equivalents	22,085	
Current assets	33,088	
Net property & equip.	38	
Total assets	34,187	
Liabilities:		
Current liabilities	13,554	
Long-term debt	4,704	
Stockholders' equity	14,805	
Net current assets	19,534	

TRANSCAT TECHNOLOGIES INC.

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Net Sales	11,550	12,243
Cost & expenses	10,773	11,387
Operating income	777	856
Other income (expense), net	90	10
Net before taxes	861	858
Income taxes	115	178
Net income	746	680
Earnings common share		
Primary	\$0.10	\$0.09
Fully Diluted	\$0.10	\$0.09
Common Shares:		
Full Diluted	7,619	7,901
Year-end	7,456	7,401

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	1,944	
Inventories	14,387	
Current assets	24,945	
Net property & equip.	2,413	
Total assets	36,474	
Liabilities:		
Current liabilities	5,580	
Stockholders' equity	27,628	
Net current assets	19,365	

TRANSLATE BIO INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Cost & expenses	35,679	22,389
Operating income	(34,205)	(22,389)
Interest income	521	89
Other income (expense), net	(12)	(12)
Net before taxes	(33,684)	(22,312)
Income taxes	(486)	(1,103)
Net income	(33,198)	(21,209)
Balance for common	(33,198)	(21,394)
Earnings common share		
Primary	\$(0.74)	\$(2.35)
Fully Diluted	\$(0.74)	\$(2.35)
Common Shares:		
Full Diluted	45,005	9,092
Year-end	45,294	9,583

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	62,431	
Current assets	128,857	
Net property & equip.	10,771	
Total assets	277,736	
Liabilities:		
Current liabilities	16,763	
Stockholders' equity	95,108	
Net current assets	112,094	

TRICIDA INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Cost & expenses	37,775	20,098
Operating income	(37,775)	(20,098)
Interest expense	1,389	319
Other income (expense), net	1,267	(87)
Net income	(37,897)	(20,504)
Earnings common share		
Primary	\$(0.90)	\$(9.00)
Fully Diluted	\$(0.90)	\$(9.00)

Common Shares:		
Full Diluted	42,268	2,278
Year-end	42,676	2,302

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	21,928	
Current assets	221,986	
Net property & equip.	1,209	
Total assets	225,964	
Liabilities:		
Current liabilities	26,746	
Long-term debt	36,940	
Stockholders' equity	160,609	
Net current assets	195,240	

UNITED HEALTH PRODUCTS INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Total Revenues	29,928	29,928
Cost & expenses	2,985,897	387,468
Operating income	(2,985,897)	(357,540)
Other income (expense), net	(3,632,500)	
Net income	(2,985,897)	(3,990,040)
Earnings common share		
Primary	\$(0.02)	\$(0.02)
Fully Diluted	\$(0.02)	\$(0.02)
Common Shares:		
Full Diluted	172,172,581	168,143,298
Year-end	174,493,138	169,022,888

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	6,310	
Inventories	83,694	
Current assets	101,014	
Total assets	101,014	
Liabilities:		
Current liabilities	641,111	
Stockholders' equity	(540,097)	
Net current assets	(540,097)	

UNITED-GUARDIAN, INC.

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2019	2018
Net Sales	3,282,024	3,519,512
Cost & expenses	2,035,672	2,076,709
Operating income	1,246,352	1,442,803
Gains or losses	301,361	(101,205)
Net before taxes	1,547,713	1,341,598
Income taxes	325,019	281,736
Net income	1,222,694	1,059,862
Earnings common share		
Primary	\$0.27	\$0.23
Fully Diluted	\$0.27	\$0.23
Common Shares:		
Full Diluted	4,594,319	4,594,319
Year-end	4,594,319	4,594,319

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	499,256	
Inventories	1,324,771	
Current assets	13,141,774	
Net property & equip.	802,518	
Total assets	13,970,233	
Liabilities:		
Current liabilities	1,558,162	
Stockholders' equity	12,147,632	
Net current assets	11,583,612	

UNUM THERAPEUTICS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2019	2018
Total Revenues	3,053	2,220
Cost & expenses	14,894	9,206
Operating income	(11,841)	(6,986)
Interest income	150	81
Other income (expense), net	170	
Net income	(11,691)	(6,735)
Balance for common	(11,691)	(6,751)
Earnings common share		
Primary	\$(0.39)	\$(0.66)
Fully Diluted	\$(0.39)	\$(0.66)
Common Shares:		
Full Diluted	30,083	10,205
Year-end	30,119	10,208

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	59,114	
Current assets	69,900	
Net property & equip.	2,963	
Total assets	81,280	
Liabilities:		
Current liabilities	26,345	
Stockholders' equity	49,290	
Net current assets	43,555	

VACCINEX INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018		
Total Revenues	94	206		
Cost & expenses	9,234	5,915		
Operating income	(9,140)	(5,709)		
Interest expense		267		
Other income (expense), net	73	(1,886)		
Net income	(9,067)	(7,862)		
Balance for common	(9,067)	(7,862)		
Earnings common share				
Primary	\$(0.79)	\$(7.13)		
Fully Diluted	\$(0.79)	\$(7.13)		
Common Shares:				
Full Diluted	11,476	1,103		
Year-end	11,476	1,103		

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	8,942	
Current assets	12,750	
Net property & equip.	544	
Total assets	13,294	
Liabilities:		
Current liabilities	6,959	
Stockholders' equity	(17,628)	
Net current assets	5,791	

VERMILLION INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018		
Total Revenues	803	649		
Cost & expenses	4,522	3,484		
Operating income	(3,719)	(2,835)		
Other income (expense), net	(4)	(3)		
Net income	(3,716)	(2,850)		
Earnings common share				
Primary	\$(0.05)	\$(0.05)		
Fully Diluted	\$(0.05)	\$(0.05)		
Common Shares:				
Full Diluted	75,508	60,037		
Year-end	75,533	60,039		

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	6,174	
Inventories	98	
Current assets	7,576	
Net property & equip.	531	
Total assets	8,254	
Liabilities:		
Current liabilities	3,336	
Long-term debt	1,244	
Stockholders' equity	3,637	
Net current assets	4,240	

VICTORY CAPITAL HOLDINGS INC (DE)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018		
Total Revenues	87,479	104,964		
Cost & expenses	60,132	71,284		
Operating income	22,125	27,268		
Other income (expense), net	(83)	(6,198)		
Net before taxes	19,334	14,081		
Income taxes	4,807	3,557		
Net income	14,527	10,524		
Earnings common share				
Primary	\$0.22	\$0.17		
Fully Diluted	\$0.20	\$0.16		
Common Shares:				
Full Diluted	72,282	66,284		
Year-end	67,522	67,951		

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	66,261	
Current assets	112,876	
Net property & equip.	8,874	
Total assets	813,928	
Liabilities:		
Current liabilities	50,232	
Long-term debt	269,320	
Stockholders' equity	470,165	
Net current assets	62,644	

YYCOR MEDICAL INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018		
Cost & expenses	498,419	597,648		
Operating income	(162,838)	(314,550)		
Foreign currency	(748)	(60)		
Net income	(180,298)	(326,636)		
Balance for common	(342,483)	(488,821)		
Earnings common share				
Primary	\$(0.01)	\$(0.02)		
Fully Diluted	\$(0.01)	\$(0.02)		
Common Shares:				
Full Diluted	23,146,646	19,985,877		
Year-end	23,676,408	20,071,988		

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	101,054	
Inventories	254,386	
Current assets	769,809	
Net property & equip.	363,505	
Total assets	1,190,768	
Liabilities:		
Current liabilities	2,149,439	
Long-term debt	19,145	
Stockholders' equity	(977,816)	
Net current assets	(1,379,630)	

VYSTAR CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018		
Total Revenues	191,667	3,944		
Cost & expenses	2,195,722	1,812,870		
Operating income	(2,004,055)	(1,808,926)		
Other income (expense), net	(1,044,402)			
Gains or losses	14,945			
Net income	(3,133,174)	(1,850,374)		
Earnings common share				
Primary	\$	\$(0.01)		
Fully Diluted	\$	\$(0.01)		
Common Shares:				
Full Diluted	770,752,984	133,875,885		
Year-end	1,057,482,127	134,307,218		

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	438,164	
Inventories	595,680	
Current assets	1,054,537	
Net property & equip.	281,614	
Total assets	2,830,581	
Liabilities:		
Current liabilities	1,446,789	
Long-term debt	2,081,579	
Stockholders' equity	(697,790)	
Net current assets	(392,252)	

WAITR HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018		
Total Revenues	48,032,000			
Cost & expenses	67,387,000	230,540		
Operating income	(23,471,000)	(230,540)		
Interest income	339,000	790,086		
Other income (expense), net	50,000			
Net before taxes	(24,687,000)	559,546		
Income taxes	62,000	106,643		
Net income	(24,749,000)	452,903		
Balance for common	(24,749,000)	(192,880)		
Earnings common share				
Primary	\$(0.38)	\$(0.03)		
Fully Diluted	\$(0.38)	\$(0.03)		
Common Shares:				
Full Diluted	64,525,683	7,608,489		
Year-end	69,368,381	31,250,000		

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	43,615,000	
Current assets	59,024,000	
Net property & equip.	4,673,000	
Total assets	392,080,000	
Liabilities:		
Current liabilities	34,308,000	
Long-term debt	119,570,000	
Stockholders' equity	235,866,000	
Net current assets	24,716,000	

WAYSIDE TECHNOLOGY GROUP INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018		
Net Sales	44,858	40,552		
Cost & expenses	43,139	38,705		
Operating income	1,719	1,847		
Gains or losses	62	2		
Net before taxes	1,950	2,087		
Income taxes	487	489		
Net income	1,463	1,598		
Balance for common	1,429	1,531		
Earnings common share				
Primary	\$0.32	\$0.36		
Fully Diluted	\$0.32	\$0.36		
Common Shares:				
Full Diluted	4,404	4,301		
Year-end	4,513	4,506		

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019	
Cash & equivalents	14,062	
Inventories	1,638	
Current assets	104,199	
Net property & equip.	1,539	
Total assets	111,164	
Liabilities:		
Current liabilities	67,158	
Stockholders' equity	41,541	
Net current assets	37,041	

XCEL BRANDS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018		
Total Revenues	10,301,000	8,766,000		
Cost & expenses	8,672,000	7,143,000		
Operating income	681,000	1,212,000		
Interest expense	479,000	286,000		
Net before taxes	202,000	926,000		
Income taxes	75,000	426,000		
Net income	127,000	500,000		
Earnings common share				
Primary	\$0.01	\$0.03		
Fully Diluted	\$0.01	\$0.03		
Common Shares:				
Full Diluted	18,562,763	18,716,802		
Year-end	18,916,394	18,367,149		

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019	
Cash & equivalents	6,802,000	
Inventories	1,417,000	
Current assets	19,944,000	
Net property & equip.	3,312,000	
Total assets	152,317,000	
Liabilities:		
Current liabilities	14,217,000	
Long-term debt	18,387,000	
Stockholders' equity	101,414,000	
Net current assets	5,727,000	

XERIS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018		
Cost & expenses	25,685	11,993		
Operating income	(25,437)	(11,730)		
Interest income	671	96		
Interest expense	1,063	191		
Other income (expense), net	552	(82)		
Net income	(25,277)	(11,907)		
Earnings common share				
Primary	\$(1.07)	\$(5.49)		
Fully Diluted	\$(1.07)	\$(5.49)		
Common Shares:				
Full Diluted	23,561	2,170		

Year-end	26,880
Consolidated Balance Sheet Items, as of (\$000):	
Assets:	
Cash & equivalents	2019
Current assets	61,984
Net property & equip.....	153,445
Total assets	7,430
Liabilities:	
Current liabilities	160,970
Long-term debt	13,406
Stockholders' equity	32,141
Net current assets	107,100
	140,039

XTANT MEDICAL HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2019	2018
Total Revenues	16,726,000	17,934,000
Cost & expenses	17,235,000	18,587,000
Operating income	(668,000)	(1,657,000)
Interest expense	2,018,000	3,545,000
Other income (expense), net	(90,000)	(51,000)
Net before taxes	(2,776,000)	
Income taxes	23,000	
Net income	(2,799,000)	(5,253,000)
Earnings common share		
Primary	\$(0.21)	\$(0.70)
Fully Diluted	\$(0.21)	\$(0.70)
Common Shares:		
Full Diluted	13,170,721	7,481,550
Year-end	13,161,762	13,077,468

Consolidated Balance Sheet Items, as of (\$):

Assets:		2019
Cash & equivalents	7,097,000	
Inventories	16,526,000	
Current assets	33,580,000	
Net property & equip.....	6,382,000	
Total assets	47,065,000	
Liabilities:		
Current liabilities	11,252,000	
Long-term debt	72,795,000	
Stockholders' equity	(39,176,000)	
Net current assets	22,328,000	

Y-MABS THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2019	2018
Cost & expenses	16,253	7,479
Operating income	(16,253)	(7,479)
Net income	(15,934)	(7,483)
Earnings common share		
Primary	\$(0.47)	\$(0.28)
Fully Diluted	\$(0.47)	\$(0.28)
Common Shares:		
Full Diluted	34,194	26,750
Year-end	34,194	26,750

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2019
Cash & equivalents	134,245	
Current assets	137,034	
Net property & equip.....	400	
Total assets	139,997	
Liabilities:		
Current liabilities	10,301	
Stockholders' equity	125,513	
Net current assets	126,733	

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2019 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.